FR3122091A1 - ECOBIOLOGICAL BIPHASIC COSMETIC COMPOSITION WITH DELAYED PHASE SEPARATION - Google Patents
ECOBIOLOGICAL BIPHASIC COSMETIC COMPOSITION WITH DELAYED PHASE SEPARATION Download PDFInfo
- Publication number
- FR3122091A1 FR3122091A1 FR2104190A FR2104190A FR3122091A1 FR 3122091 A1 FR3122091 A1 FR 3122091A1 FR 2104190 A FR2104190 A FR 2104190A FR 2104190 A FR2104190 A FR 2104190A FR 3122091 A1 FR3122091 A1 FR 3122091A1
- Authority
- FR
- France
- Prior art keywords
- polyglyceryl
- advantageously
- composition according
- cosmetic composition
- caprate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 149
- 239000002537 cosmetic Substances 0.000 title claims abstract description 35
- 230000002051 biphasic effect Effects 0.000 title claims abstract description 33
- 238000005191 phase separation Methods 0.000 title description 4
- 230000003111 delayed effect Effects 0.000 title description 3
- 239000012071 phase Substances 0.000 claims abstract description 49
- 239000008346 aqueous phase Substances 0.000 claims abstract description 42
- 239000004094 surface-active agent Substances 0.000 claims abstract description 29
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 claims abstract description 22
- -1 fatty acid esters Chemical class 0.000 claims abstract description 21
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 claims abstract description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229940097941 polyglyceryl-10 laurate Drugs 0.000 claims abstract description 13
- 229940070765 laurate Drugs 0.000 claims abstract description 11
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 10
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 claims abstract description 10
- 239000000194 fatty acid Substances 0.000 claims abstract description 10
- 229930195729 fatty acid Natural products 0.000 claims abstract description 10
- 229940087068 glyceryl caprylate Drugs 0.000 claims abstract description 9
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 claims abstract description 9
- 229940080812 glyceryl caprate Drugs 0.000 claims abstract description 6
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims abstract description 5
- GJVUMEONPPTZEY-UHFFFAOYSA-N 2,3-dihydroxypropyl undec-10-enoate Chemical compound OCC(O)COC(=O)CCCCCCCCC=C GJVUMEONPPTZEY-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229940075529 glyceryl stearate Drugs 0.000 claims abstract description 5
- 229940074050 glyceryl myristate Drugs 0.000 claims abstract description 4
- 229920001296 polysiloxane Polymers 0.000 claims abstract description 4
- DCBSHORRWZKAKO-UHFFFAOYSA-N rac-1-monomyristoylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OCC(O)CO DCBSHORRWZKAKO-UHFFFAOYSA-N 0.000 claims abstract description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 25
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 19
- BANXPJUEBPWEOT-UHFFFAOYSA-N 2-methyl-Pentadecane Chemical compound CCCCCCCCCCCCCC(C)C BANXPJUEBPWEOT-UHFFFAOYSA-N 0.000 claims description 18
- SGVYKUFIHHTIFL-UHFFFAOYSA-N Isobutylhexyl Natural products CCCCCCCC(C)C SGVYKUFIHHTIFL-UHFFFAOYSA-N 0.000 claims description 17
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims description 16
- GTJOHISYCKPIMT-UHFFFAOYSA-N 2-methylundecane Chemical compound CCCCCCCCCC(C)C GTJOHISYCKPIMT-UHFFFAOYSA-N 0.000 claims description 13
- VKPSKYDESGTTFR-UHFFFAOYSA-N isododecane Natural products CC(C)(C)CC(C)CC(C)(C)C VKPSKYDESGTTFR-UHFFFAOYSA-N 0.000 claims description 13
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 10
- 210000004209 hair Anatomy 0.000 claims description 10
- 229940043268 2,2,4,4,6,8,8-heptamethylnonane Drugs 0.000 claims description 9
- 239000000839 emulsion Substances 0.000 claims description 9
- KUVMKLCGXIYSNH-UHFFFAOYSA-N isopentadecane Natural products CCCCCCCCCCCCC(C)C KUVMKLCGXIYSNH-UHFFFAOYSA-N 0.000 claims description 9
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 claims description 8
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims description 8
- 229960002446 octanoic acid Drugs 0.000 claims description 8
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 8
- 150000002148 esters Chemical class 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 238000004140 cleaning Methods 0.000 claims description 5
- 150000004665 fatty acids Chemical class 0.000 claims description 5
- 229960001950 benzethonium chloride Drugs 0.000 claims description 4
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 claims description 4
- 235000011187 glycerol Nutrition 0.000 claims description 4
- 150000002314 glycerols Chemical class 0.000 claims description 4
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 229940032094 squalane Drugs 0.000 claims description 4
- LKUNXBRZDFMZOK-GFCCVEGCSA-N Capric acid monoglyceride Natural products CCCCCCCCCC(=O)OC[C@H](O)CO LKUNXBRZDFMZOK-GFCCVEGCSA-N 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 229940074046 glyceryl laurate Drugs 0.000 claims description 3
- LKUNXBRZDFMZOK-UHFFFAOYSA-N rac-1-monodecanoylglycerol Chemical compound CCCCCCCCCC(=O)OCC(O)CO LKUNXBRZDFMZOK-UHFFFAOYSA-N 0.000 claims description 3
- ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 claims description 3
- 150000003648 triterpenes Chemical class 0.000 claims description 3
- 150000002170 ethers Chemical class 0.000 claims description 2
- 239000003349 gelling agent Substances 0.000 claims description 2
- 230000003204 osmotic effect Effects 0.000 claims description 2
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 43
- 239000000284 extract Substances 0.000 description 10
- 238000009472 formulation Methods 0.000 description 9
- 230000010363 phase shift Effects 0.000 description 9
- 239000003755 preservative agent Substances 0.000 description 9
- 239000002994 raw material Substances 0.000 description 8
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 7
- IIYFAKIEWZDVMP-UHFFFAOYSA-N tridecane Chemical compound CCCCCCCCCCCCC IIYFAKIEWZDVMP-UHFFFAOYSA-N 0.000 description 7
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 150000002191 fatty alcohols Chemical class 0.000 description 6
- 229920002545 silicone oil Polymers 0.000 description 6
- BGHCVCJVXZWKCC-UHFFFAOYSA-N tetradecane Chemical compound CCCCCCCCCCCCCC BGHCVCJVXZWKCC-UHFFFAOYSA-N 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 5
- 108010087806 Carnosine Proteins 0.000 description 5
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 230000002335 preservative effect Effects 0.000 description 5
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 4
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229940044199 carnosine Drugs 0.000 description 4
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 210000004400 mucous membrane Anatomy 0.000 description 4
- BKIMMITUMNQMOS-UHFFFAOYSA-N nonane Chemical compound CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- RSJKGSCJYJTIGS-UHFFFAOYSA-N undecane Chemical compound CCCCCCCCCCC RSJKGSCJYJTIGS-UHFFFAOYSA-N 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- SNRUBQQJIBEYMU-UHFFFAOYSA-N dodecane Chemical compound CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 3
- YCOZIPAWZNQLMR-UHFFFAOYSA-N heptane - octane Natural products CCCCCCCCCCCCCCC YCOZIPAWZNQLMR-UHFFFAOYSA-N 0.000 description 3
- VVOAZFWZEDHOOU-UHFFFAOYSA-N magnolol Chemical compound OC1=CC=C(CC=C)C=C1C1=CC(CC=C)=CC=C1O VVOAZFWZEDHOOU-UHFFFAOYSA-N 0.000 description 3
- 229940094933 n-dodecane Drugs 0.000 description 3
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 3
- 235000013772 propylene glycol Nutrition 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 3
- KJXSIXMJHKAJOD-LSDHHAIUSA-N (+)-dihydromyricetin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC(O)=C(O)C(O)=C1 KJXSIXMJHKAJOD-LSDHHAIUSA-N 0.000 description 2
- NKJOXAZJBOMXID-UHFFFAOYSA-N 1,1'-Oxybisoctane Chemical compound CCCCCCCCOCCCCCCCC NKJOXAZJBOMXID-UHFFFAOYSA-N 0.000 description 2
- 229940015975 1,2-hexanediol Drugs 0.000 description 2
- JSOVGYMVTPPEND-UHFFFAOYSA-N 16-methylheptadecyl 2,2-dimethylpropanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)C(C)(C)C JSOVGYMVTPPEND-UHFFFAOYSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- QWGRWMMWNDWRQN-UHFFFAOYSA-N 2-methylpropane-1,3-diol Chemical compound OCC(C)CO QWGRWMMWNDWRQN-UHFFFAOYSA-N 0.000 description 2
- JOOXCMJARBKPKM-UHFFFAOYSA-N 4-oxopentanoic acid Chemical compound CC(=O)CCC(O)=O JOOXCMJARBKPKM-UHFFFAOYSA-N 0.000 description 2
- 244000118350 Andrographis paniculata Species 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 2
- MLSJBGYKDYSOAE-DCWMUDTNSA-N L-Ascorbic acid-2-glucoside Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1O MLSJBGYKDYSOAE-DCWMUDTNSA-N 0.000 description 2
- 241000206754 Palmaria palmata Species 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- 240000006365 Vitis vinifera Species 0.000 description 2
- 235000014787 Vitis vinifera Nutrition 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- ANVAOWXLWRTKGA-XHGAXZNDSA-N all-trans-alpha-carotene Chemical compound CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1C(C)=CCCC1(C)C ANVAOWXLWRTKGA-XHGAXZNDSA-N 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 229940067599 ascorbyl glucoside Drugs 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 2
- YSRSBDQINUMTIF-UHFFFAOYSA-N decane-1,2-diol Chemical compound CCCCCCCCC(O)CO YSRSBDQINUMTIF-UHFFFAOYSA-N 0.000 description 2
- PKPOVTYZGGYDIJ-UHFFFAOYSA-N dioctyl carbonate Chemical compound CCCCCCCCOC(=O)OCCCCCCCC PKPOVTYZGGYDIJ-UHFFFAOYSA-N 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 235000019800 disodium phosphate Nutrition 0.000 description 2
- XJFGDLJQUJQUEI-UHFFFAOYSA-N dodecyl decanoate dodecyl octanoate Chemical compound CCCCCCCCCCCCOC(=O)CCCCCCC.CCCCCCCCCCCCOC(=O)CCCCCCCCC XJFGDLJQUJQUEI-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 2
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical class OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- AEIJTFQOBWATKX-UHFFFAOYSA-N octane-1,2-diol Chemical compound CCCCCCC(O)CO AEIJTFQOBWATKX-UHFFFAOYSA-N 0.000 description 2
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- PJANXHGTPQOBST-VAWYXSNFSA-N trans-stilbene Chemical compound C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 2
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 2
- 239000011686 zinc sulphate Substances 0.000 description 2
- 235000009529 zinc sulphate Nutrition 0.000 description 2
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- WZHKXNSOCOQYQX-FUAFALNISA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 WZHKXNSOCOQYQX-FUAFALNISA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- IZFHEQBZOYJLPK-SSDOTTSWSA-N (R)-dihydrolipoic acid Chemical compound OC(=O)CCCC[C@@H](S)CCS IZFHEQBZOYJLPK-SSDOTTSWSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- ODJQKYXPKWQWNK-UHFFFAOYSA-N 3,3'-Thiobispropanoic acid Chemical compound OC(=O)CCSCCC(O)=O ODJQKYXPKWQWNK-UHFFFAOYSA-N 0.000 description 1
- UIVPNOBLHXUKDX-UHFFFAOYSA-N 3,5,5-trimethylhexyl 3,5,5-trimethylhexanoate Chemical compound CC(C)(C)CC(C)CCOC(=O)CC(C)CC(C)(C)C UIVPNOBLHXUKDX-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- QJZYHAIUNVAGQP-UHFFFAOYSA-N 3-nitrobicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid Chemical compound C1C2C=CC1C(C(=O)O)C2(C(O)=O)[N+]([O-])=O QJZYHAIUNVAGQP-UHFFFAOYSA-N 0.000 description 1
- GWXXFGWOWOJEEX-UHFFFAOYSA-N 4,4,4-trihydroxy-1-phenylbutan-1-one Chemical compound OC(CCC(=O)C1=CC=CC=C1)(O)O GWXXFGWOWOJEEX-UHFFFAOYSA-N 0.000 description 1
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 1
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 108010085443 Anserine Proteins 0.000 description 1
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N Arbutin Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 1
- 244000139693 Arctostaphylos uva ursi Species 0.000 description 1
- 235000012871 Arctostaphylos uva ursi Nutrition 0.000 description 1
- XHVAWZZCDCWGBK-WYRLRVFGSA-M Aurothioglucose Chemical compound OC[C@H]1O[C@H](S[Au])[C@H](O)[C@@H](O)[C@@H]1O XHVAWZZCDCWGBK-WYRLRVFGSA-M 0.000 description 1
- LFYJSSARVMHQJB-UHFFFAOYSA-N Backuchiol Natural products CC(C)=CCCC(C)(C=C)C=CC1=CC=C(O)C=C1 LFYJSSARVMHQJB-UHFFFAOYSA-N 0.000 description 1
- GWZYPXHJIZCRAJ-UHFFFAOYSA-N Biliverdin Natural products CC1=C(C=C)C(=C/C2=NC(=Cc3[nH]c(C=C/4NC(=O)C(=C4C)C=C)c(C)c3CCC(=O)O)C(=C2C)CCC(=O)O)NC1=O GWZYPXHJIZCRAJ-UHFFFAOYSA-N 0.000 description 1
- RCNSAJSGRJSBKK-NSQVQWHSSA-N Biliverdin IX Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(\C=C/2C(=C(C)C(=C/C=3C(=C(C=C)C(=O)N=3)C)/N\2)CCC(O)=O)N1 RCNSAJSGRJSBKK-NSQVQWHSSA-N 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- BVIFGCDWCOXAAS-UHFFFAOYSA-N C(CCCCCCCCCCC)(=O)OCC(O)CO.C(CCCCCCCCCCCCC)(=O)OCC(O)CO Chemical compound C(CCCCCCCCCCC)(=O)OCC(O)CO.C(CCCCCCCCCCCCC)(=O)OCC(O)CO BVIFGCDWCOXAAS-UHFFFAOYSA-N 0.000 description 1
- KNFLNGRLKALWRF-LDXSYGEZSA-N CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)CC1=CC=CC=C1 Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)CC1=CC=CC=C1 KNFLNGRLKALWRF-LDXSYGEZSA-N 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- LAAPRQODJPXAHC-UHFFFAOYSA-N Coniferyl benzoate Natural products C1=C(O)C(OC)=CC(C=CCOC(=O)C=2C=CC=CC=2)=C1 LAAPRQODJPXAHC-UHFFFAOYSA-N 0.000 description 1
- 235000005956 Cosmos caudatus Nutrition 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 1
- 230000028937 DNA protection Effects 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- GHKOFFNLGXMVNJ-UHFFFAOYSA-N Didodecyl thiobispropanoate Chemical compound CCCCCCCCCCCCOC(=O)CCSCCC(=O)OCCCCCCCCCCCC GHKOFFNLGXMVNJ-UHFFFAOYSA-N 0.000 description 1
- VIZORQUEIQEFRT-UHFFFAOYSA-N Diethyl adipate Chemical compound CCOC(=O)CCCCC(=O)OCC VIZORQUEIQEFRT-UHFFFAOYSA-N 0.000 description 1
- 239000003508 Dilauryl thiodipropionate Substances 0.000 description 1
- 239000002656 Distearyl thiodipropionate Substances 0.000 description 1
- RPWFJAMTCNSJKK-UHFFFAOYSA-N Dodecyl gallate Chemical compound CCCCCCCCCCCCOC(=O)C1=CC(O)=C(O)C(O)=C1 RPWFJAMTCNSJKK-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 240000008917 Glycyrrhiza uralensis Species 0.000 description 1
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 description 1
- CMBYOWLFQAFZCP-UHFFFAOYSA-N Hexyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCC CMBYOWLFQAFZCP-UHFFFAOYSA-N 0.000 description 1
- BYTORXDZJWWIKR-UHFFFAOYSA-N Hinokiol Natural products CC(C)c1cc2CCC3C(C)(CO)C(O)CCC3(C)c2cc1O BYTORXDZJWWIKR-UHFFFAOYSA-N 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 229940124091 Keratolytic Drugs 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- SLRNWACWRVGMKD-UHFFFAOYSA-N L-anserine Natural products CN1C=NC(CC(NC(=O)CCN)C(O)=O)=C1 SLRNWACWRVGMKD-UHFFFAOYSA-N 0.000 description 1
- KJQFBVYMGADDTQ-CVSPRKDYSA-N L-buthionine-(S,R)-sulfoximine Chemical compound CCCCS(=N)(=O)CC[C@H](N)C(O)=O KJQFBVYMGADDTQ-CVSPRKDYSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- SAVLIIGUQOSOEP-UHFFFAOYSA-N N-octanoylglycine Chemical compound CCCCCCCC(=O)NCC(O)=O SAVLIIGUQOSOEP-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- GVCMITUTKAQVPW-UHFFFAOYSA-N P1(OCCCCO1)=O.C(CN)N.[Na].[Na].[Na].[Na].[Na] Chemical compound P1(OCCCCO1)=O.C(CN)N.[Na].[Na].[Na].[Na].[Na] GVCMITUTKAQVPW-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 241000210053 Potentilla elegans Species 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- VYGQUTWHTHXGQB-UHFFFAOYSA-N Retinol hexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- RJFAYQIBOAGBLC-BYPYZUCNSA-N Selenium-L-methionine Chemical compound C[Se]CC[C@H](N)C(O)=O RJFAYQIBOAGBLC-BYPYZUCNSA-N 0.000 description 1
- RJFAYQIBOAGBLC-UHFFFAOYSA-N Selenomethionine Natural products C[Se]CCC(N)C(O)=O RJFAYQIBOAGBLC-UHFFFAOYSA-N 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000003490 Thiodipropionic acid Substances 0.000 description 1
- 102000002933 Thioredoxin Human genes 0.000 description 1
- CKZZREIPBTYJEQ-UHFFFAOYSA-N Totarol Natural products C1CC2C(C)(C)CCCC2(C)C2=C1C(C(C)C)=C(C)C=C2 CKZZREIPBTYJEQ-UHFFFAOYSA-N 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- OEWBEINAQKIQLZ-CMRBMDBWSA-N [(2s)-2-[(2r)-3,4-bis(2-hexyldecanoyloxy)-5-oxo-2h-furan-2-yl]-2-(2-hexyldecanoyloxy)ethyl] 2-hexyldecanoate Chemical compound CCCCCCCCC(CCCCCC)C(=O)OC[C@H](OC(=O)C(CCCCCC)CCCCCCCC)[C@H]1OC(=O)C(OC(=O)C(CCCCCC)CCCCCCCC)=C1OC(=O)C(CCCCCC)CCCCCCCC OEWBEINAQKIQLZ-CMRBMDBWSA-N 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- 235000003903 alpha-carotene Nutrition 0.000 description 1
- 239000011795 alpha-carotene Substances 0.000 description 1
- ANVAOWXLWRTKGA-HLLMEWEMSA-N alpha-carotene Natural products C(=C\C=C\C=C(/C=C/C=C(\C=C\C=1C(C)(C)CCCC=1C)/C)\C)(\C=C\C=C(/C=C/[C@H]1C(C)=CCCC1(C)C)\C)/C ANVAOWXLWRTKGA-HLLMEWEMSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- ASLUCFFROXVMFL-UHFFFAOYSA-N andrographolide Natural products CC1(CO)C(O)CCC2(C)C(CC=C3/C(O)OCC3=O)C(=C)CCC12 ASLUCFFROXVMFL-UHFFFAOYSA-N 0.000 description 1
- MYYIAHXIVFADCU-QMMMGPOBSA-N anserine Chemical compound CN1C=NC=C1C[C@H](NC(=O)CC[NH3+])C([O-])=O MYYIAHXIVFADCU-QMMMGPOBSA-N 0.000 description 1
- 239000000058 anti acne agent Substances 0.000 description 1
- 230000003255 anti-acne Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000002225 anti-radical effect Effects 0.000 description 1
- 229940124340 antiacne agent Drugs 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 229940070313 arctostaphylos uva-ursi leaf extract Drugs 0.000 description 1
- 229960001799 aurothioglucose Drugs 0.000 description 1
- LFYJSSARVMHQJB-GOSISDBHSA-N bakuchinol Natural products CC(C)=CCC[C@@](C)(C=C)C=CC1=CC=C(O)C=C1 LFYJSSARVMHQJB-GOSISDBHSA-N 0.000 description 1
- LFYJSSARVMHQJB-QIXNEVBVSA-N bakuchiol Chemical compound CC(C)=CCC[C@@](C)(C=C)\C=C\C1=CC=C(O)C=C1 LFYJSSARVMHQJB-QIXNEVBVSA-N 0.000 description 1
- 229940117895 bakuchiol Drugs 0.000 description 1
- KXXXNMZPAJTCQY-UHFFFAOYSA-N bakuchiol Natural products CC(C)CCCC(C)(C=C)C=Cc1ccc(O)cc1 KXXXNMZPAJTCQY-UHFFFAOYSA-N 0.000 description 1
- ISAOCJYIOMOJEB-UHFFFAOYSA-N benzoin Chemical compound C=1C=CC=CC=1C(O)C(=O)C1=CC=CC=C1 ISAOCJYIOMOJEB-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- QBUVFDKTZJNUPP-UHFFFAOYSA-N biliverdin-IXalpha Natural products N1C(=O)C(C)=C(C=C)C1=CC1=C(C)C(CCC(O)=O)=C(C=C2C(=C(C)C(C=C3C(=C(C=C)C(=O)N3)C)=N2)CCC(O)=O)N1 QBUVFDKTZJNUPP-UHFFFAOYSA-N 0.000 description 1
- 230000003592 biomimetic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940051368 capryloyl glycine Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- LAAPRQODJPXAHC-AATRIKPKSA-N coniferyl benzoate Chemical compound C1=C(O)C(OC)=CC(\C=C\COC(=O)C=2C=CC=CC=2)=C1 LAAPRQODJPXAHC-AATRIKPKSA-N 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 description 1
- 229940099500 cystamine Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- JDRSMPFHFNXQRB-IBEHDNSVSA-N decyl glucoside Chemical compound CCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JDRSMPFHFNXQRB-IBEHDNSVSA-N 0.000 description 1
- 235000019258 dehydroacetic acid Nutrition 0.000 description 1
- 229940061632 dehydroacetic acid Drugs 0.000 description 1
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 1
- KQILIWXGGKGKNX-UHFFFAOYSA-N dihydromyricetin Natural products OC1C(=C(Oc2cc(O)cc(O)c12)c3cc(O)c(O)c(O)c3)O KQILIWXGGKGKNX-UHFFFAOYSA-N 0.000 description 1
- 229940031578 diisopropyl adipate Drugs 0.000 description 1
- 235000019304 dilauryl thiodipropionate Nutrition 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- PWWSSIYVTQUJQQ-UHFFFAOYSA-N distearyl thiodipropionate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)CCSCCC(=O)OCCCCCCCCCCCCCCCCCC PWWSSIYVTQUJQQ-UHFFFAOYSA-N 0.000 description 1
- 235000019305 distearyl thiodipropionate Nutrition 0.000 description 1
- 239000000555 dodecyl gallate Substances 0.000 description 1
- 235000010386 dodecyl gallate Nutrition 0.000 description 1
- 229940080643 dodecyl gallate Drugs 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 description 1
- 239000010696 ester oil Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 210000000720 eyelash Anatomy 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229940106580 ginkgo biloba leaf extract Drugs 0.000 description 1
- 229940093767 glabridin Drugs 0.000 description 1
- PMPYOYXFIHXBJI-ZDUSSCGKSA-N glabridin Natural products C1([C@H]2CC=3C=CC4=C(C=3OC2)CCC(O4)(C)C)=CC=C(O)C=C1O PMPYOYXFIHXBJI-ZDUSSCGKSA-N 0.000 description 1
- LBQIJVLKGVZRIW-UHFFFAOYSA-N glabridine Natural products C1OC2=C3C=CC(C)(C)OC3=CC=C2CC1C1=CC=C(O)C=C1O LBQIJVLKGVZRIW-UHFFFAOYSA-N 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 125000005908 glyceryl ester group Chemical group 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- 229940084760 glycyrrhiza inflata root extract Drugs 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 235000002532 grape seed extract Nutrition 0.000 description 1
- 239000003722 gum benzoin Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940100463 hexyl laurate Drugs 0.000 description 1
- 229940051250 hexylene glycol Drugs 0.000 description 1
- FVYXIJYOAGAUQK-UHFFFAOYSA-N honokiol Chemical compound C1=C(CC=C)C(O)=CC=C1C1=CC(CC=C)=CC=C1O FVYXIJYOAGAUQK-UHFFFAOYSA-N 0.000 description 1
- 239000004021 humic acid Substances 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- VVIUBCNYACGLLV-UHFFFAOYSA-N hypotaurine Chemical compound [NH3+]CCS([O-])=O VVIUBCNYACGLLV-UHFFFAOYSA-N 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940100554 isononyl isononanoate Drugs 0.000 description 1
- 229940093629 isopropyl isostearate Drugs 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940040102 levulinic acid Drugs 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960003951 masoprocol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000021332 multicellular organism growth Effects 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 229940048869 o-cymen-5-ol Drugs 0.000 description 1
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 1
- HRPZGPXWSVHWPB-UHFFFAOYSA-N octyl decanoate Chemical compound CCCCCCCCCC(=O)OCCCCCCCC HRPZGPXWSVHWPB-UHFFFAOYSA-N 0.000 description 1
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- BARWIPMJPCRCTP-CLFAGFIQSA-N oleyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC BARWIPMJPCRCTP-CLFAGFIQSA-N 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 229940098695 palmitic acid Drugs 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- ZEYHEAKUIGZSGI-UHFFFAOYSA-N para-methoxy benzoic acid Natural products COC1=CC=C(C(O)=O)C=C1 ZEYHEAKUIGZSGI-UHFFFAOYSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 229940116406 poloxamer 184 Drugs 0.000 description 1
- 229940100861 polyglyceryl-3 laurate Drugs 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- NEOZOXKVMDBOSG-UHFFFAOYSA-N propan-2-yl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OC(C)C NEOZOXKVMDBOSG-UHFFFAOYSA-N 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960002662 propylthiouracil Drugs 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229960002718 selenomethionine Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- YRWWOAFMPXPHEJ-OFBPEYICSA-K sodium L-ascorbic acid 2-phosphate Chemical compound [Na+].[Na+].[Na+].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1[O-] YRWWOAFMPXPHEJ-OFBPEYICSA-K 0.000 description 1
- 229940048058 sodium ascorbyl phosphate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- ARCJQKUWGAZPFX-UHFFFAOYSA-N stilbene oxide Chemical compound O1C(C=2C=CC=CC=2)C1C1=CC=CC=C1 ARCJQKUWGAZPFX-UHFFFAOYSA-N 0.000 description 1
- 150000001629 stilbenes Chemical class 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 125000005555 sulfoximide group Chemical group 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 235000019303 thiodipropionic acid Nutrition 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- ZRVDANDJSTYELM-FXAWDEMLSA-N totarol Chemical compound CC([C@@H]1CC2)(C)CCC[C@]1(C)C1=C2C(C(C)C)=C(O)C=C1 ZRVDANDJSTYELM-FXAWDEMLSA-N 0.000 description 1
- 229940074347 totarol Drugs 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N trans-Stilbene Natural products C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- ZRVDANDJSTYELM-UHFFFAOYSA-N trans-totarol Natural products C1CC2C(C)(C)CCCC2(C)C2=C1C(C(C)C)=C(O)C=C2 ZRVDANDJSTYELM-UHFFFAOYSA-N 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
- A61Q1/14—Preparations for removing make-up
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/03—Liquid compositions with two or more distinct layers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/31—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/39—Derivatives containing from 2 to 10 oxyalkylene groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/30—Characterized by the absence of a particular group of ingredients
- A61K2800/34—Free of silicones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Cosmetics (AREA)
Abstract
L’invention concerne une composition cosmétique biphasique écobiologique comprenant une phase aqueuse et une phase grasse distinctes se présentant sous la forme de deux phases non miscibles présentes chacune sous forme continue, ladite composition comprend au moins un tensioactif choisi parmi les esters d'un acide gras et de glycérol sélectionné dans le groupe constitué du laurate de polyglycéryl-10, caprylate de polyglycéryl-3, caprate de polyglycéryl-3, caprate de polyglycéryl-4, laurate de polyglycéryl-2, laurate de polyglycéryl-5, caprylate de glycéryle, laurate de glycéryle, myristate de glycéryle, stéarate de glycéryle, undécylénate de glycéryle et caprylate/caprate de glycéryle ;ladite phase grasse étant exempte de silicone.The invention relates to an ecobiological biphasic cosmetic composition comprising an aqueous phase and a distinct fatty phase in the form of two immiscible phases, each present in continuous form, said composition comprising at least one surfactant chosen from fatty acid esters and glycerol selected from the group consisting of polyglyceryl-10 laurate, polyglyceryl-3 caprylate, polyglyceryl-3 caprate, polyglyceryl-4 caprate, polyglyceryl-2 laurate, polyglyceryl-5 laurate, glyceryl caprylate, laurate glyceryl, glyceryl myristate, glyceryl stearate, glyceryl undecylenate and glyceryl caprylate/caprate;said fatty phase being free of silicone.
Description
Domaine technique de l’inventionTechnical field of the invention
La présente invention se rapporte au domaine des soins cosmétiques, et plus particulièrement des compositions cosmétiques biphasiques. Plus précisément, l’invention concerne une composition cosmétique biphasique écobiologique pour application topique et son utilisation, notamment dans un procédé de démaquillage, de nettoyage et/ou de soin topique.The present invention relates to the field of cosmetic care, and more particularly to biphasic cosmetic compositions. More specifically, the invention relates to an ecobiological biphasic cosmetic composition for topical application and its use, in particular in a process for removing make-up, cleansing and/or topical care.
Etat de la techniqueState of the art
Les compositions conventionnelles, par exemple les compositions démaquillantes, peuvent se présenter sous différentes formes galéniques, par exemple une huile, une lotion micellaire, un gel, ou encore une composition biphasique. Cette dernière est constituée de deux phases distinctes, notamment d'une phase aqueuse et d'une phase grasse, et se distinguent d’une émulsion classique ou stable par le fait qu’au repos, les deux phases sont distinctes au lieu d'être émulsionnées l'une dans l'autre. L'utilisation d’une composition biphasique nécessite une agitation préalable afin de former une émulsion extemporanée, celle-ci ayant pour objectif d’assurer une application homogène des deux phases sur une surface kératinique telle que la peau. Au repos, les deux phases de la composition biphasique se séparent plus ou moins rapidement et retrouvent leur état d’origine, c’est-à-dire sous la forme de deux phases distinctes, ce phénomène étant plus connu sous le terme de « déphasage ».Conventional compositions, for example makeup-removing compositions, can be in different galenic forms, for example an oil, a micellar lotion, a gel, or else a biphasic composition. The latter consists of two distinct phases, in particular an aqueous phase and a fatty phase, and differs from a conventional or stable emulsion in that, at rest, the two phases are distinct instead of being emulsified into each other. The use of a biphasic composition requires prior agitation in order to form an extemporaneous emulsion, the purpose of which is to ensure homogeneous application of the two phases on a keratin surface such as the skin. At rest, the two phases of the biphasic composition separate more or less quickly and return to their original state, that is to say in the form of two distinct phases, this phenomenon being better known under the term "phase shift". ".
Parmi les compositions biphasiques, notamment les compositions démaquillantes, connues de l’état de la technique, on peut citer, la composition démaquillante biphasée comprenant au moins un alkylpolyglucoside non éthoxylé et des huiles siliconées décrite dans le document FR 2 993 177.Among the biphasic compositions, in particular make-up removing compositions, known to the state of the art, mention may be made of the two-phase make-up removing composition comprising at least one non-ethoxylated alkyl polyglucoside and silicone oils described in document FR 2 993 177.
Le document FR 3 012 330 décrit une composition constituée d'une phase aqueuse et d'une phase grasse distinctes et transparentes comprenant des huiles siliconées et au moins un tensioactif spécifique en ce qu’il présente un équilibre hydrophile/lipophile (ou HLB) inférieur à 8 et se présente sous une forme liquide à température ambiante.Document FR 3 012 330 describes a composition consisting of an aqueous phase and a distinct and transparent fatty phase comprising silicone oils and at least one specific surfactant in that it has a lower hydrophilic/lipophilic balance (or HLB). to 8 and is in a liquid form at room temperature.
Le document FR 2 971 421 décrit une composition démaquillante biphasée constituée d’une phase aqueuse comprenant au moins un polycondensat d'oxyde d'éthylène et d'oxyde de propylène ; et d’une phase grasse comprenant au moins une huile ester d'acide gras et des huiles siliconées cycliques par rapport au poids total de la phase grasse.Document FR 2 971 421 describes a two-phase makeup-removing composition consisting of an aqueous phase comprising at least one polycondensate of ethylene oxide and propylene oxide; and a fatty phase comprising at least one fatty acid ester oil and cyclic silicone oils relative to the total weight of the fatty phase.
Le document FR2 935 264 décrit une composition démaquillante biphasée comprenant au moins un alcane linéaire volatile et au moins une huile additionnelle, notamment une huile siliconée.Document FR2 935 264 describes a two-phase makeup-removing composition comprising at least one volatile linear alkane and at least one additional oil, in particular a silicone oil.
Cependant, ces compositions présentent plusieurs inconvénients. En particulier, la phase grasse est principalement constituée d’huiles siliconées (ou silicones), qui sont des composés non écobiologiques, considérés comme des polluants environnementaux et dont l’utilisation est désormais critiquée. De surcroit, les compositions traditionnelles souffrent de l’inconvénient majeur de se déphaser très rapidement après l’étape d’agitation préalable à la formation d’une émulsion extemporanée, obligeant l’utilisateur à agiter plusieurs fois le produit avant son utilisation et qui ne garantit pas une application homogène de la composition sur la peau de l’utilisateur.However, these compositions have several drawbacks. In particular, the fatty phase is mainly made up of silicone oils (or silicones), which are non-ecobiological compounds, considered as environmental pollutants and whose use is now criticized. In addition, the traditional compositions suffer from the major drawback of being phase-shifted very quickly after the stirring step prior to the formation of an extemporaneous emulsion, forcing the user to shake the product several times before using it and which does not does not guarantee a homogeneous application of the composition on the skin of the user.
Il subsiste donc un besoin évident de mettre au point une formulation cosmétique qui soit écobiologique, qui assure une application homogène d’une composition biphasique, qui soit facile d’utilisation, c’est-à-dire qui ne nécessite pas de répéter son agitation pour obtenir l’émulsion applicable par exemple sur la peau et qui soit respectueuse de la santé de l’utilisateur et qui permette de respecter l’environnement.There therefore remains an obvious need to develop a cosmetic formulation which is eco-biological, which ensures homogeneous application of a biphasic composition, which is easy to use, that is to say which does not require repeated agitation. to obtain the emulsion applicable for example on the skin and which is respectful of the health of the user and which makes it possible to respect the environment.
Description de l’inventionDescription of the invention
Le Demandeur a constaté que, de manière surprenante, l’invention fournit pour la première fois une solution à l’ensemble des problèmes techniques définis précédemment. Ainsi, l'utilisation d’une classe particulière de tensioactifs dans la formulation d’une composition biphasique comportant une phase grasse et une phase aqueuse permet d'obtenir un produit cosmétique ayant les qualités recherchées, c’est-à-dire, caractérisée notamment par une séparation de phases retardée et pourvue en plus de bonnes propriétés galéniques, d’hydratation et de nettoyage des surface kératiniques dont la peau. En outre, la séparation de phases retardée observée dans la composition selon l’invention n’empêche pas aux deux phases de se retrouver parfaitement séparées au stockage, ce qui assure la transparence du produit au repos et limite les interactions entre les deux phases.The Applicant has found that, surprisingly, the invention provides for the first time a solution to all the technical problems defined above. Thus, the use of a particular class of surfactants in the formulation of a biphasic composition comprising a fatty phase and an aqueous phase makes it possible to obtain a cosmetic product having the desired qualities, that is to say, characterized in particular by a delayed phase separation and provided in addition with good galenic properties, hydration and cleaning of keratinous surfaces including the skin. In addition, the delayed phase separation observed in the composition according to the invention does not prevent the two phases from being perfectly separated on storage, which ensures the transparency of the product at rest and limits the interactions between the two phases.
Au sens de l’invention, par « temps de déphasage » on désigne le temps mis par la composition, après agitation, pour revenir à son état initial dans lequel la phase aqueuse et la phase grasse sont distinctes l'une de l'autre.Within the meaning of the invention, the term “phase shift time” denotes the time taken by the composition, after agitation, to return to its initial state in which the aqueous phase and the fatty phase are distinct from each other.
Au sens de l’invention, par « surfaces kératiniques » on désigne la peau, les quasi-muqueuses et muqueuses, les poils dont cils et sourcils, les cheveux, le cuir chevelu et les ongles.Within the meaning of the invention, by “keratinous surfaces” is meant the skin, the quasi-mucous membranes and mucous membranes, the hairs including eyelashes and eyebrows, the hair, the scalp and the nails.
La présente invention a pour objet une composition cosmétique biphasique écobiologique comprenant une phase aqueuse et une phase grasse distinctes se présentant sous la forme de deux phases non miscibles présentes chacune sous forme continue,
ladite composition comprend au moins un tensioactif,
ledit tensioactif étant un ester d'acide gras et de glycérol sélectionné dans le groupe constitué du laurate de polyglycéryl-10, caprylate de polyglycéryl-3, caprate de polyglycéryl-3, caprate de polyglycéryl-4, laurate de polyglycéryl-2, laurate de polyglycéryl-5, caprylate de glycéryle, laurate de glycéryle, myristate de glycéryle, stéarate de glycéryle, undécylénate de glycéryle et caprylate/caprate de glycéryle ;
ladite phase grasse étant exempte de silicone, c’est-à-dire exempte d’huile siliconée.The subject of the present invention is an ecobiological biphasic cosmetic composition comprising an aqueous phase and a distinct fatty phase in the form of two immiscible phases, each present in continuous form,
said composition comprises at least one surfactant,
said surfactant being a glycerol fatty acid ester selected from the group consisting of polyglyceryl-10 laurate, polyglyceryl-3 caprylate, polyglyceryl-3 caprate, polyglyceryl-4 caprate, polyglyceryl-2 laurate, polyglyceryl-5, glyceryl caprylate, glyceryl laurate, glyceryl myristate, glyceryl stearate, glyceryl undecylenate and glyceryl caprylate/caprate;
said fatty phase being free of silicone, that is to say free of silicone oil.
Comme mentionné précédemment, la composition selon l'invention comprend une phase aqueuse et une phase grasse. Ces deux phases sont distinctes, c'est-à-dire qu'elles se séparent l'une au-dessus de l'autre et qu'elles apparaissent visuellement comme non mélangées au repos. Avantageusement, la phase aqueuse constitue la phase inférieure tandis que la phase grasse constitue la phase supérieure. En d’autres termes, la composition selon l’invention se présente sous la forme de deux phases miscibles présentes chacune sous forme continue. Les deux phases peuvent être ou non colorées. Avantageusement, les deux phases sont transparentes.As mentioned previously, the composition according to the invention comprises an aqueous phase and a fatty phase. These two phases are distinct, that is, they separate one above the other and visually appear as unmixed at rest. Advantageously, the aqueous phase constitutes the lower phase while the fatty phase constitutes the upper phase. In other words, the composition according to the invention is in the form of two miscible phases, each present in continuous form. The two phases may or may not be colored. Advantageously, the two phases are transparent.
Selon un mode de réalisation particulier, le au moins un tensioactif est compris dans la phase aqueuse. Alternativement, le au moins un tensioactif est compris dans la phase grasse.According to a particular embodiment, the at least one surfactant is included in the aqueous phase. Alternatively, the at least one surfactant is included in the fatty phase.
Selon un autre mode de réalisation particulier, la composition selon l’invention comprend plusieurs tensioactifs tels que décrits précédemment, avantageusement présents dans la phase aqueuse et/ou la phase grasse.According to another particular embodiment, the composition according to the invention comprises several surfactants as described above, advantageously present in the aqueous phase and/or the fatty phase.
Selon un mode de réalisation particulier, le tensioactif est sélectionné dans le groupe constitué par laurate de polyglycéryl-10, caprylate de polyglycéryl-3, caprate de polyglycéryl-3, caprate de polyglycéryl-4, laurate de polyglycéryl-2 et laurate de polyglycéryl-5, avantageusement le tensioactif est le laurate de polyglycéryl-10.According to a particular embodiment, the surfactant is selected from the group consisting of polyglyceryl-10 laurate, polyglyceryl-3 caprylate, polyglyceryl-3 caprate, polyglyceryl-4 caprate, polyglyceryl-2 laurate and polyglyceryl-3 laurate. 5, advantageously the surfactant is polyglyceryl-10 laurate.
Selon un autre mode de réalisation particulier, la composition de l’invention comprend un seul tensioactif qui est, avantageusement, présent dans la phase aqueuse.According to another particular embodiment, the composition of the invention comprises a single surfactant which is advantageously present in the aqueous phase.
Avantageusement, la composition de l’invention comprend pour seul tensioactif le laurate de polyglycéryl-10 qui est, de préférence, présent dans la phase aqueuse.Advantageously, the composition of the invention comprises, as sole surfactant, polyglyceryl-10 laurate which is preferably present in the aqueous phase.
Selon un mode de réalisation particulier, le au moins un tensioactif représente entre 0,00001% et 5% en poids total de la composition, avantageusement entre 0,0001% et 0,1%.According to a particular embodiment, the at least one surfactant represents between 0.00001% and 5% by total weight of the composition, advantageously between 0.0001% and 0.1%.
Avantageusement, des tensioactifs du type ester d'acide gras et de glycérol aptes à être utilisés dans la composition selon l’invention sont disponibles sur le marché auprès de plusieurs fournisseurs.Advantageously, surfactants of the fatty acid and glycerol ester type suitable for use in the composition according to the invention are available on the market from several suppliers.
A titre d’exemple, les matières premières suivantes peuvent être mises en œuvre dans la composition selon l’invention :
- le Lexgard™ GMC commercialisé par la société INOLEX INC. et correspondant à la désignation INCI Glyceryl Caprate ;
- le TEGO™ COSMO P813 et TEGOSOFT™ PC 41 commercialisé par la société EVONIK et correspondant respectivement à la désignation INCI Polyglyceryl-3 Caprylate et Polyglyceryl-4 Caprate ;
- le Dub LG, Dub MG, Dub GMS et Dub MUG commercialisés par la société STEARINERIE DUBOIS FILS et correspondant respectivement à la désignation INCI glyceryl laurate glyceryl myristate, glyceryl stearate, glyceryl undecylenate et glyceryl caprylate/Caprate ;
- le Dermofeel™ G 2 L et Dermofeel™ G 5 L commercialisés par la société DR. STRAETMANS GMBH et correspondant respectivement à la désignation INCI polyglyceryl-2 laurate et polyglyceryl-5 laurate ;
- le Dermofeel G 10 L commercialisé par la société DR. STRAETMANS GMBHet correspondant à la désignation INCI polyglyceryl-10 laurate.By way of example, the following raw materials can be used in the composition according to the invention:
- Lexgard™ GMC marketed by the company INOLEX INC. and corresponding to the INCI designation Glyceryl Caprate;
- TEGO™ COSMO P813 and TEGOSOFT™ PC 41 marketed by the company EVONIK and corresponding respectively to the INCI designation Polyglyceryl-3 Caprylate and Polyglyceryl-4 Caprate;
- Dub LG, Dub MG, Dub GMS and Dub MUG marketed by the company STEARINERIE DUBOIS FILS and corresponding respectively to the INCI designation glyceryl laurate glyceryl myristate, glyceryl stearate, glyceryl undecylenate and glyceryl caprylate/Caprate;
- Dermofeel™ G 2 L and Dermofeel™ G 5 L marketed by the company DR. STRAETMANS GMBH and corresponding respectively to the INCI designation polyglyceryl-2 laurate and polyglyceryl-5 laurate;
- Dermofeel G 10 L marketed by the company DR. STRAETMANS GMBHet corresponding to the INCI designation polyglyceryl-10 laurate.
Afin d’assurer de bonnes propriétés hydratantes, la composition selon l’invention est riche en eau. Ainsi et selon un mode de réalisation particulier, l’eau représente au moins 20% en poids total de la composition, avantageusement entre 50% et 80%, de préférence entre 50% et 70%.In order to ensure good moisturizing properties, the composition according to the invention is rich in water. Thus and according to a particular embodiment, the water represents at least 20% by total weight of the composition, advantageously between 50% and 80%, preferably between 50% and 70%.
Selon un mode de réalisation particulier, le ratio de phase grasse/phase aqueuse de la composition de l’invention est compris entre 1/10 et 2/1, avantageusement entre 1/4 et 1/1.According to a particular embodiment, the ratio of fatty phase/aqueous phase of the composition of the invention is between 1/10 and 2/1, advantageously between 1/4 and 1/1.
Dans un mode de réalisation particulier, la phase aqueuse de la composition biphasique au sens de l’invention est formulée avec une eau de formulation correspondant à une solution aqueuse saline et minéralisée répondant à au moins deux paramètres bioélectriques ou bioélectriques, dont l'un est le potentiel redox, et dont l'autre est choisi entre le pH et la résistivité. Cette eau est en équilibre électronique avec l’eau cellulaire et donc particulièrement adaptée à l’application topique.In a particular embodiment, the aqueous phase of the biphasic composition within the meaning of the invention is formulated with a water of formulation corresponding to a saline and mineralized aqueous solution corresponding to at least two bioelectric or bioelectric parameters, one of which is the redox potential, and the other of which is chosen between the pH and the resistivity. This water is in electronic equilibrium with the cellular water and therefore particularly suitable for topical application.
Ainsi et selon un mode de réalisation particulier au moins deux paramètres bioélectriques de la phase aqueuse de la composition biphasique selon l’invention, dont l'un est le potentiel redox, et dont l'autre est choisi entre le pH et la résistivité, sont réglés pour avoir une valeur:
- comprise entre 4 et 8, en ce qui concerne le pH ;
- comprise entre 10 et 300 mV, en ce qui concerne le potentiel redox ; et
- substantiellement comprise entre 33 et 8000 Ohms.cm, en ce qui concerne la résistivité.Thus and according to a particular embodiment, at least two bioelectric parameters of the aqueous phase of the biphasic composition according to the invention, one of which is the redox potential, and the other of which is chosen between the pH and the resistivity, are set to have a value:
- between 4 and 8, as regards the pH;
- between 10 and 300 mV, as regards the redox potential; and
- substantially between 33 and 8000 Ohms.cm, as far as the resistivity is concerned.
Selon un mode de réalisation particulier, la phase aqueuse de la composition biphasique selon l’invention possède une conductivité substantiellement comprise entre 125 et 30000 μS/cm.According to a particular embodiment, the aqueous phase of the biphasic composition according to the invention has a conductivity substantially between 125 and 30,000 μS/cm.
Selon un mode de réalisation particulier, la pression osmotique de la phase aqueuse de la composition biphasique selon l’invention a une valeur comprise entre 70 et 3000 mOsmole/Kg, de préférence entre 200 et 2000 mOsmole/Kg.According to a particular embodiment, the osmotic pressure of the aqueous phase of the two-phase composition according to the invention has a value of between 70 and 3000 mOsmol/Kg, preferably between 200 and 2000 mOsmol/Kg.
A titre d'exemple, ce sont les trois paramètres bioélectriques de la phase aqueuse de la composition biphasique selon l’invention définie précédemment, qui sont réglés par la composition minérale, pour avoir les valeurs définies ci-dessus, respectivement pour le pH, le potentiel redox et la résistivité.By way of example, it is the three bioelectric parameters of the aqueous phase of the biphasic composition according to the invention defined above, which are regulated by the mineral composition, to have the values defined above, respectively for the pH, the redox potential and resistivity.
Selon un mode de réalisation particulier, en plus de l’eau, la phase aqueuse de la composition biphasique selon l’invention comprend du chlorure de calcium ; du chlorure de potassium ; du phosphate de potassium ; du sulfate de magnésium ; du chlorure de sodium ; de l’hydrogénocarbonate de sodium ; de l’hydrogénophosphate de sodium ; du citrate de sodium ; de l’acide citrique ; de la carnosine ; utilisés seuls ou en mélangeAccording to a particular embodiment, in addition to water, the aqueous phase of the biphasic composition according to the invention comprises calcium chloride; potassium chloride; potassium phosphate; magnesium sulfate; sodium chloride; sodium hydrogen carbonate; sodium hydrogen phosphate; sodium citrate; citric acid; carnosine; used alone or in combination
Selon un mode de réalisation particulier, la phase aqueuse de la composition biphasique selon l’invention comprend :
- du chlorure de calcium représentant entre 0,000001% et 0,1% en poids total de la phase aqueuse , avantageusement entre 0,0001% et 0,1% ;
- du chlorure de potassium représentant entre 0,0001% et 0,1% en poids total de la phase aqueuse , avantageusement entre 0,001% et 0,1% ;
- du phosphate de potassium représentant entre 0,00001% et 0,1% en poids total de la phase aqueuse , avantageusement entre 0,0001% et 0,1% ;
- du sulfate de magnésium représentant entre 0,0001% et 0,1% en poids total de la phase aqueuse , avantageusement entre 0,001% et 0,1% ;
- du chlorure de sodium représentant entre 0,001% et 4% en poids total de la phase aqueuse, avantageusement entre 0,1% et 4%;
- de l’hydrogénocarbonate de sodium représentant entre 0,0001% et 0,1% en poids total de la phase aqueuse;
- de l’hydrogénophosphate de sodium représentant entre 0,0001% et 0,1% en poids total de la phase aqueuse ;
- de l’acide citrique représentant entre 0,0001% et 1% en poids total de la phase aqueuse, avantageusement entre 0,001% et 1% ;
- du citrate de sodium représentant entre 0,001% et 1% en poids total de la phase aqueuse ;
- de la carnosine représentant entre 0,0001% et 1% en poids total de la phase aqueuse de carnosine, avantageusement de entre 0,001% et 1% ; et
- de l’acide 2-aminoéthanesulfinique représentant entre 0,0001% et 1% en poids total de la phase aqueuse, avantageusement entre 0,001% et 1%.According to a particular embodiment, the aqueous phase of the biphasic composition according to the invention comprises:
- calcium chloride representing between 0.000001% and 0.1% by total weight of the aqueous phase, advantageously between 0.0001% and 0.1%;
- potassium chloride representing between 0.0001% and 0.1% by total weight of the aqueous phase, advantageously between 0.001% and 0.1%;
- potassium phosphate representing between 0.00001% and 0.1% by total weight of the aqueous phase, advantageously between 0.0001% and 0.1%;
- magnesium sulphate representing between 0.0001% and 0.1% by total weight of the aqueous phase, advantageously between 0.001% and 0.1%;
- sodium chloride representing between 0.001% and 4% by total weight of the aqueous phase, advantageously between 0.1% and 4%;
- sodium hydrogen carbonate representing between 0.0001% and 0.1% by total weight of the aqueous phase;
- sodium hydrogen phosphate representing between 0.0001% and 0.1% by total weight of the aqueous phase;
- citric acid representing between 0.0001% and 1% by total weight of the aqueous phase, advantageously between 0.001% and 1%;
- sodium citrate representing between 0.001% and 1% by total weight of the aqueous phase;
- carnosine representing between 0.0001% and 1% by total weight of the aqueous phase of carnosine, advantageously between 0.001% and 1%; and
- 2-aminoethanesulfinic acid representing between 0.0001% and 1% by total weight of the aqueous phase, advantageously between 0.001% and 1%.
Selon un mode de réalisation particulier, la phase grasse de l’invention comprend au moins une huile qui est, avantageusement, sélectionnée dans le groupe constitué par les alcanes ramifiés, les alcanes linéaires, les esters, de préférence ramifiés, les éthers, les triterpènes et les dérivés huileux de glycérine.According to a particular embodiment, the fatty phase of the invention comprises at least one oil which is advantageously selected from the group consisting of branched alkanes, linear alkanes, preferably branched esters, ethers, triterpenes and oily derivatives of glycerine.
Selon un autre mode de réalisation particulier, la composition biphasique selon l’invention comprend au moins une huile sélectionnée dans le groupe constitué par :
-les alcanes ramifiés comprenant de préférence de 8 à 19 atomes de carbone et avantageusement sélectionnés dans le groupe constitué par l'isododécane, l'isodécane, l'isohexadécane, le C15-19 Alkane (dénomination INCI) et leurs mélanges, de préférence l’isohéxadecane et l’isododécane ;
- les dérivés huileux de glycérine, avantageusement les triglycérides d'acide caprique et/ou caprylique, le caprylate de glycérol, le caprate de glycérol et/ou le polyglyceryl-2 caprate ;
- les alcanes linéaires comprenant de 7 à 14 atomes de carbone ;
- les esters issus de la réaction d'au moins un acide gras comportant au moins 6 atomes de carbone, avantageusement de 6 à 26 atomes de carbone ;
- les éthers d'alcools gras comprenant de 6 à 20 atomes de carbone, avantageusement de 8 à 12 atomes de carbone, de préférence de 8 à 10 atomes de carbone ; et
- les triterpènes, avantageusement le squalane.According to another particular embodiment, the biphasic composition according to the invention comprises at least one oil selected from the group consisting of:
- branched alkanes preferably comprising from 8 to 19 carbon atoms and advantageously selected from the group consisting of isododecane, isodecane, isohexadecane, C15-19 Alkane (INCI name) and mixtures thereof, preferably l isohexadecane and isododecane;
- oily glycerol derivatives, advantageously capric and/or caprylic acid triglycerides, glycerol caprylate, glycerol caprate and/or polyglyceryl-2 caprate;
- linear alkanes comprising from 7 to 14 carbon atoms;
- esters resulting from the reaction of at least one fatty acid comprising at least 6 carbon atoms, advantageously from 6 to 26 carbon atoms;
- fatty alcohol ethers comprising from 6 to 20 carbon atoms, advantageously from 8 to 12 carbon atoms, preferably from 8 to 10 carbon atoms; and
- triterpenes, advantageously squalane.
A titre d’exemple d’alcanes ramifiés adaptés à la formulation dans une composition biphasique selon l’invention on peut citer :
-la matière première ISODODECANE commercialisée par la société INEOS OLIGOMERS GmBH et correspondant à la désignation INCI isododecane ;
- la matière première ARLAMOL™ HD-LQ-(RB) commercialisée par la société CRODA et correspondant à la désignation INCI isohexadecane ; et
- la matière première EMOGREEN™ L15 commercialisée par la société SEPPIC et correspondant à la désignation INCI C15-19 Alkane.By way of example of branched alkanes suitable for formulation in a two-phase composition according to the invention, mention may be made of:
- the raw material ISODODECANE marketed by the company INEOS OLIGOMERS GmBH and corresponding to the INCI designation isododecane;
- the raw material ARLAMOL™ HD-LQ-(RB) marketed by the company CRODA and corresponding to the INCI designation isohexadecane; and
- the raw material EMOGREEN™ L15 marketed by the company SEPPIC and corresponding to the INCI designation C15-19 Alkane.
A titre d'exemple d'alcanes linéaires selon l'invention, on peut citer le n-heptane (C7), le n-octane (C8), le n-nonane (C9), le n-décane (010), le n-undécane (C11), le n-dodécane (C12), le n-tridécane (C13), le n-tétradécane (C14), et leurs mélanges.By way of example of linear alkanes according to the invention, mention may be made of n-heptane (C7), n-octane (C8), n-nonane (C9), n-decane (010), n-undecane (C11), n-dodecane (C12), n-tridecane (C13), n-tetradecane (C14), and mixtures thereof.
Selon un mode de réalisation particulier, l'alcane linéaire est sélectionné dans le groupe constitué par le n-nonane, le n-undécane, le n-dodécane, le n-tridécane, le n-tétradécane, et leurs mélanges.According to a particular embodiment, the linear alkane is selected from the group consisting of n-nonane, n-undecane, n-dodecane, n-tridecane, n-tetradecane, and mixtures thereof.
Selon un mode de réalisation particulier, l'alcane linéaire correspond au mélange de n-undécane (C11) et de n-tridécane (C13) tel que celui vendu par la société BASF sous la référence CETIOL™ ULTIMATE.According to a particular embodiment, the linear alkane corresponds to the mixture of n-undecane (C11) and n-tridecane (C13) such as that sold by the company BASF under the reference CETIOL™ ULTIMATE.
Selon un autre mode de réalisation particulier, l'alcane linéaire est le n-dodécane tel que celui vendu sous la référence PARAFOL 12-97 par SASOL.According to another particular embodiment, the linear alkane is n-dodecane such as that sold under the reference PARAFOL 12-97 by SASOL.
Selon un autre mode de réalisation particulier, l'alcane linéaire est le n-tétradécane tel que celui vendu sous la référence PARAFOL 14-97 par SASOL.According to another particular embodiment, the linear alkane is n-tetradecane such as that sold under the reference PARAFOL 14-97 by SASOL.
Selon l’invention, plusieurs types d’esters sont adaptés à l’utilisation dans la composition biphasique selon l’invention.According to the invention, several types of esters are suitable for use in the biphasic composition according to the invention.
Selon un mode de réalisation particulier, on peut citer en particulier les esters issus de la réaction d'au moins un acide gras comportant au moins 6 atomes de carbone, avantageusement de 6 à 26 atomes de carbone, de préférence de 6 à 20 atomes de carbone, plus préférentiellement de 6 à 16 atomes de carbone et d'au moins un alcool comprenant de 1 à 17 atomes de carbone et mieux de 3 à 15 atomes de carbone ; on peut citer notamment le myristate d'isopropyle, l'isostéarate d'isopropyle, le palmitate d'isopropyle, le caprate/caprylate d'ethyl 2-hexyle (ou caprate/caprylate d'octyle), le palmitate d'éthyl-2-hexyle, le néopentanoate d'isostéaryle, l'isononanoate d'isononyle, le laurate d'hexyle, les esters d'acide lactique et d'alcools gras comprenant 12 ou 13 atomes de carbone et/ou le carbonate de dicaprylyle.According to a particular embodiment, mention may be made in particular of the esters resulting from the reaction of at least one fatty acid comprising at least 6 carbon atoms, advantageously from 6 to 26 carbon atoms, preferably from 6 to 20 carbon atoms. carbon, more preferably from 6 to 16 carbon atoms and at least one alcohol comprising from 1 to 17 carbon atoms and better still from 3 to 15 carbon atoms; mention may be made in particular of isopropyl myristate, isopropyl isostearate, isopropyl palmitate, ethyl 2-hexyl caprate/caprylate (or octyl caprate/caprylate), ethyl-2 -hexyl, isostearyl neopentanoate, isononyl isononanoate, hexyl laurate, esters of lactic acid and fatty alcohols comprising 12 or 13 carbon atoms and/or dicaprylyl carbonate.
Selon un mode de réalisation particulier, l’ester selon l’invention correspond au mélange d'esters d'acides caprylique/caprique et d'alcools gras en C12-C18 tel que le coco-caprylate/ caprate.According to a particular embodiment, the ester according to the invention corresponds to the mixture of esters of caprylic/capric acids and C12-C18 fatty alcohols such as coco-caprylate/caprate.
Selon un mode de réalisation particulier, l’éther selon l’invention est un éther d'alcool gras comprenant de 6 à 20 atomes de carbone, avantageusement de 8 à 12 atomes de carbone, de préférence de 8 à 10 atomes de carbone. Ce type d’éther peut être obtenu à partir de deux alcools gras différents ou de deux alcools gras identiques. De préférence, il est obtenu à partir de deux alcools gras identiques tel que l'alcool caprylique (encore appelé octan-1 -ol ou n-octanol) et correspond au dicaprylyl éther.According to a particular embodiment, the ether according to the invention is a fatty alcohol ether comprising from 6 to 20 carbon atoms, advantageously from 8 to 12 carbon atoms, preferably from 8 to 10 carbon atoms. This type of ether can be obtained from two different fatty alcohols or from two identical fatty alcohols. Preferably, it is obtained from two identical fatty alcohols such as caprylic alcohol (also called octan-1-ol or n-octanol) and corresponds to dicaprylyl ether.
A titre d’exemple, ces matières premières sont disponibles auprès de la société STEARINERIE DUBOIS (produits DUB) et BASF (gamme CETIOL) sous les références suivantes :
- le Dub DEA correspondant à la désignation INCI diethyl adipate ;
- le Dub DIS correspondant à la désignation INCI diisopropyl adipate ;
- le Dub VCI 18 correspondant à la désignation INCI isostearyl neopentanoate ;By way of example, these raw materials are available from STEARINERIE DUBOIS (DUB products) and BASF (CETIOL range) under the following references:
- the Dub DEA corresponding to the INCI designation diethyl adipate;
- the Dub DIS corresponding to the INCI designation diisopropyl adipate;
- Dub VCI 18 corresponding to the INCI designation isostearyl neopentanoate;
-le Dub IPP correspondant à la désignation INCI isopropyl palmitate ;
- le CETIOL CC correspondant à la désignation INCI dicaprylyl carbonate ;
- le CETIOL LC correspondant à la désignation INCI coco-caprylate/caprate ; et
- le CETIOL OE correspondant à la désignation INCI dicaprylyl ether.- the Dub IPP corresponding to the INCI designation isopropyl palmitate;
- CETIOL CC corresponding to the INCI designation dicaprylyl carbonate;
- CETIOL LC corresponding to the INCI designation coco-caprylate/caprate; and
- CETIOL OE corresponding to the INCI designation dicaprylyl ether.
Selon un mode de réalisation particulier, le triterpène utilisé dans la composition de l’invention est le squalane. Avantageusement, le squalane est d’origine végétal. A titre d’exemple, on peut citer la matière première PHYOSQUALAN commercialisée par la société SOPHIM.According to a particular embodiment, the triterpene used in the composition of the invention is squalane. Advantageously, the squalane is of vegetable origin. By way of example, we can cite the raw material PHYOSQUALAN marketed by the company SOPHIM.
Selon un mode de réalisation particulier, les dérivés huileux de glycérine utilisés dans la composition de l’invention sont les triglycérides d'acide caprique et/ou caprylique, par exemple la matière première Captex™ 355 commercialisée par la société ABITEC corporation et correspondant à la désignation INCI caprylic/capric triglyceride.According to a particular embodiment, the oily glycerin derivatives used in the composition of the invention are capric and/or caprylic acid triglycerides, for example the raw material Captex™ 355 marketed by the company ABITEC corporation and corresponding to the INCI designation caprylic/capric triglyceride.
Selon un mode de réalisation particulier, la composition selon l’invention comprend :
- au moins un alcane ramifié comprenant de 8 à 16 atomes de carbone tels que l'isododécane, l'isodécane, l'isohexadécane et leurs mélanges ; et/ou
- au moins un dérivé huileux de glycérine comme par exemple les triglycérides d'acide caprique et/ou caprylique, le caprylate ou caprate de glycérol, le polyglyceryl-2 caprate.According to a particular embodiment, the composition according to the invention comprises:
- at least one branched alkane comprising from 8 to 16 carbon atoms such as isododecane, isodecane, isohexadecane and mixtures thereof; and or
- at least one oily derivative of glycerin such as for example capric and/or caprylic acid triglycerides, glycerol caprylate or caprate, polyglyceryl-2 caprate.
Selon un mode de réalisation particulier, la composition selon l’invention, en particulier la phase grasse, comprend de l'isododécane, de l'isohexadécane et les triglycérides d'acide caprique et/ou caprylique.According to a particular embodiment, the composition according to the invention, in particular the fatty phase, comprises isododecane, isohexadecane and capric and/or caprylic acid triglycerides.
Selon un mode de réalisation particulier de l’invention, le ratio isododécane/isohexadécane est compris entre 1:2 et 2:1 et en ce que les triglycérides d'acide caprique et/ou caprylique représentent entre 0,5% et 10% en poids total de la composition, avantageusement entre 1% et 2%.According to a particular embodiment of the invention, the isododecane/isohexadecane ratio is between 1:2 and 2:1 and in that the capric and/or caprylic acid triglycerides represent between 0.5% and 10% by total weight of the composition, advantageously between 1% and 2%.
Selon un mode de réalisation particulier de l’invention, la phase grasse correspond de 5% à 50% en poids total de la composition, avantageusement de 10% à 40%.According to a particular embodiment of the invention, the fatty phase corresponds from 5% to 50% by total weight of the composition, advantageously from 10% to 40%.
Selon un mode de réalisation particulier, la composition selon l’invention est exempte de chlorure de benzéthonium et/ou de gélifiant.According to a particular embodiment, the composition according to the invention is free of benzethonium chloride and/or gelling agent.
Selon un mode de réalisation particulier, la composition de l’invention est une composition démaquillante ou une composition de nettoyage et/ou de soin des surfaces kératiniques, de préférence la peau, les muqueuses et les phanères (c’est-à-dire les cheveux, poils et ongles).According to a particular embodiment, the composition of the invention is a makeup-removing composition or a composition for cleaning and/or caring for keratinous surfaces, preferably the skin, the mucous membranes and the superficial body growths (that is to say the hair, body hair and nails).
Avantageusement la composition de l’invention est une composition démaquillante.Advantageously, the composition of the invention is a makeup-removing composition.
La composition selon l'invention étant destinée à une application topique, elle contient un milieu physiologiquement acceptable, c'est-à-dire compatible avec la peau, les muqueuses, les ongles, les poils, les cheveux et le cuir chevelu. La composition peut être notamment une composition cosmétique ou dermatologique.Since the composition according to the invention is intended for topical application, it contains a physiologically acceptable medium, that is to say one which is compatible with the skin, the mucous membranes, the nails, the body hair, the hair and the scalp. The composition may in particular be a cosmetic or dermatological composition.
Dans un mode de réalisation particulier, la composition selon l’invention comprend en outre d’autres composants pouvant contribuer à la protection interne par une action qui peut consister en une protection de l'ADN, une diminution de l'immunosuppression induite par les radiations UV, une action antiradicalaire ou un effet combiné de ces actions.In a particular embodiment, the composition according to the invention also comprises other components which can contribute to internal protection by an action which can consist of DNA protection, a reduction in the immunosuppression induced by radiation UV, an antiradical action or a combined effect of these actions.
L'action protectrice d’une composition biphasique selon l’invention contre le stress oxydatif ou à l'encontre de l'effet des radicaux libres peut être encore améliorée si celle-ci comprend en outre un ou plusieurs antioxydants, aisément sélectionnées par l'homme du métier par exemple dans la liste suivante : le totarol, le magnolol, l’honokiol, les acides aminés et leurs dérivés, des peptides (D et/ou L-carnosine) et leurs dérivés (par exemple l’ansérine, l’hypotaurine, la taurine), les caroténoïdes, les carotènes (α-carotène, β-carotène, lycopène) et leurs dérivés, l'acide chlorogénique et ses dérivés, l'acide lipoïque et ses dérivés (acide dihydrolipoïque), l’aurothioglucose, le propylthiouracile et autres thiols (thiorédoxine, glutathion, cystéine, cystine, cystamine et leurs esters glycosyle, N-acétyle, méthyle, éthyle, propyle, amyle, butyle et lauryle, palmitoyle, oléyle, γ-linoléique, cholestéryle et glycéryle) ainsi que des sels de ceux-ci, le thiodipropionate de dilauryle, le thiodipropionate de distéaryle, l'acide thiodipropionique et ses dérivés, les composés sulfoximine (sulfoximine de buthionine, l'homocystéine sulfoximine, les buthionine sulfones, penta-, hexa- et heptathionine sulfoximine), des agents chélatants (tels que les acides α-hydroxygras, l'acide palmitique, l'acide phytique, la lactoferrine), les α-hydroxyacides (tels que l'acide citrique, lactique, ou malique), l'acide humique, l'acide biliaire, les extraits de bile, la bilirubine, la biliverdine, le tétraméthylène phosphonate pentasodique d'éthylènediamine et ses dérivés, les acides gras insaturés et leurs dérivés, la vitamine A et ses dérivés (palmitate de vitamine A), le benzoate de coniféryle de la résine de benjoin, l'acide rutinique et ses dérivés, l'α-glycosyl rutine, l’acide férulique et ses dérivés, le furfurylideneglucitol, la carnosine, le butylhydroxytoluène, le butylhydroxyanisole, l'acide nordihydroguaiarétique, trihydroxybutyrophenone, la quercétine, l'acide urique et ses dérivés, le mannose et les dérivés de ceux-ci, le zinc et ses dérivés (ZnO, ZnSO4), le sélénium et ses dérivés (sélénométhionine), les stilbènes et leurs dérivés (l'oxyde de stilbène, l'oxyde trans-stilbène).The protective action of a biphasic composition according to the invention against oxidative stress or against the effect of free radicals can be further improved if the latter also comprises one or more antioxidants, easily selected by the skilled in the art, for example from the following list: totarol, magnolol, honokiol, amino acids and their derivatives, peptides (D and/or L-carnosine) and their derivatives (for example anserine, hypotaurine, taurine), carotenoids, carotenes (α-carotene, β-carotene, lycopene) and their derivatives, chlorogenic acid and its derivatives, lipoic acid and its derivatives (dihydrolipoic acid), aurothioglucose, propylthiouracil and other thiols (thioredoxin, glutathione, cysteine, cystine, cystamine and their glycosyl, N-acetyl, methyl, ethyl, propyl, amyl, butyl and lauryl, palmitoyl, oleyl, γ-linoleic, cholesterol and glyceryl esters) as well as salts thereof, dilauryl thiodipropionate, distearyl thiodipropionate, thiodipropionic acid and its derivatives, sulfoximine compounds (buthionine sulfoximine, homocysteine sulfoximine, buthionine sulfones, penta-, hexa-, and heptathionine sulfoximine), chelating agents (such as α-hydroxy fatty acids , palmitic acid, phytic acid, lactoferrin), α-hydroxy acids (such as citric, lactic, or malic acid), humic acid, bile acid, bile extracts, bilirubin , biliverdin, ethylenediamine pentasodium tetramethylene phosphonate and its derivatives, unsaturated fatty acids and their derivatives, vitamin A and its derivatives (vitamin A palmitate), coniferyl benzoate of benzoin resin, rutinic acid and its derivatives, α-glycosyl rutin, ferulic acid and its derivatives, furfurylideneglucitol, carnosine, butylhydroxytoluene, butylhydroxyanisole, nordihydroguaiaretic acid, trihydroxybutyrophenone, quercetin, uric acid and its derivatives ives, mannose and derivatives thereof, zinc and its derivatives (ZnO, ZnSO 4 ), selenium and its derivatives (selenomethionine), stilbenes and their derivatives (stilbene oxide, trans- stilbene).
Dans un mode de réalisation particulier, la composition selon l’invention comprend en outre de l’acide glycyrrhétinique, un dérivé ou un sel de cet acide, utilisé comme apaisant (agent anti-inflammatoire) et représentant entre 0,01% et 2 % en poids total de la composition, de préférence entre 0,1% et 1%.In a particular embodiment, the composition according to the invention also comprises glycyrrhetinic acid, a derivative or a salt of this acid, used as a soothing agent (anti-inflammatory agent) and representing between 0.01% and 2% by total weight of the composition, preferably between 0.1% and 1%.
La composition selon l’invention peut également contenir des actifs ayant des propriétés dépigmentantes, par exemple :
- de l’azéilate de lysine, ou d’autres dérivés ou sels de l’acide azélaïque ;
- de l’andrographolide, notamment l’extrait d’Andrographis paniculatacorrespondant à la désignation INCIAndrographis paniculataleaf extract ;
- de l’acide ascorbique natif (vitamine C) ou ses dérivés, notamment les dérivés correspondant aux INCI ascorbyl glucoside, ethyl ascorbic acid, ascorbyl methylsilanol pectinate, sodium ascorbyl phosphate et ascorbyl tetraisopalmitate, avantageusement l’ascorbyl glucoside ;
- de l’arbutine ou un extrait végétal la contenant, notamment l’extrait de busserole correspondant à la désignation INCIArctostaphylos uva-ursileaf extract ;
- de la glabridine ou un extrait végétal la contenant, notamment les extraits de réglisse correspondant à la désignation INCIGlycyrrhiza glabraroot extract,Glycyrrhiza inflataroot extract, Glycyrrhiza uralensisroot extract ;
- les peptides biomimétiques correspondant aux désignations INCI hexapeptide-2 et/ou nonapeptide-1 ;
- un extrait aqueux d'une algue dénomméePalmaria palmata, notamment l’extrait correspondant à la désignation INCIPalmaria palmataextract ;
- le 4-n-butylresorcinol ;
- de la vitamine PP, également appelée niacinamide ou nicotinamide, et ses dérivés ; et/ou
- de leurs mélanges.The composition according to the invention may also contain active agents with depigmenting properties, for example:
- lysine azeilate, or other derivatives or salts of azelaic acid;
- andrographolide, in particular the extract of Andrographis paniculata corresponding to the INCI designation Andrographis paniculata leaf extract;
- native ascorbic acid (vitamin C) or its derivatives, in particular the derivatives corresponding to the INCI ascorbyl glucoside, ethyl ascorbic acid, ascorbyl methylsilanol pectinate, sodium ascorbyl phosphate and ascorbyl tetraisopalmitate, advantageously ascorbyl glucoside;
- arbutin or a plant extract containing it, in particular bearberry extract corresponding to the INCI designation Arctostaphylos uva-ursi leaf extract;
- glabridin or a plant extract containing it, in particular liquorice extracts corresponding to the INCI designation Glycyrrhiza glabra root extract, Glycyrrhiza inflata root extract , Glycyrrhiza uralensis root extract;
- biomimetic peptides corresponding to the INCI designations hexapeptide-2 and/or nonapeptide-1;
- an aqueous extract of an alga called Palmaria palmata , in particular the extract corresponding to the INCI designation Palmaria palmata extract;
- 4-n-butylresorcinol;
- vitamin PP, also called niacinamide or nicotinamide, and its derivatives; and or
- their mixtures.
La composition selon l’invention peut également contenir des actifs ayant des propriétés cicatrisantes, par exemple, un agent antimicrobien choisi parmi les actifs correspondant aux désignations INCI suivantes : copper sulfate, zinc sulfate, sodium hyaluronate,Vitis vinifera(grape) vine extract, ou leurs mélanges.The composition according to the invention may also contain active agents having healing properties, for example, an antimicrobial agent chosen from the active agents corresponding to the following INCI designations: copper sulphate, zinc sulphate, sodium hyaluronate, Vitis vinifera (grape) vine extract, or their mixtures.
La composition selon l’invention peut également contenir des actifs ayant des propriétés sébocorrectrices, kératolytiques, séboregulatrices et/ou une activité antiacnéique, afin de permettre la formulation de produits traitant l’acné. Par exemple, la composition selon l’invention peut comprendre un agent antimicrobien ou anti-acnéique choisi parmi les actifs correspondant aux désignations INCI propyl gallate, dodecyl gallate,Ginkgo bilobaleaf extract, bakuchiol, dihydromyricetine, zinc gluconate, salicylic acid, ou leurs mélanges.The composition according to the invention may also contain active agents having sebum-correcting, keratolytic, sebum-regulating properties and/or an anti-acne activity, in order to allow the formulation of products treating acne. For example, the composition according to the invention may comprise an antimicrobial or anti-acne agent chosen from the active agents corresponding to the INCI designations propyl gallate, dodecyl gallate, Ginkgo biloba leaf extract, bakuchiol, dihydromyricetin, zinc gluconate, salicylic acid, or mixtures thereof. .
Avantageusement, la composition selon l’invention comprend en outre au moins un agent conservateur.Advantageously, the composition according to the invention also comprises at least one preservative.
La plupart des conservateurs, autorisés ou non autorisés par la réglementation (annexe V de la Directive européenne sur les produits cosmétiques), aptes à être utilisé dans des compositions cosmétiques ou dermatologiques peut être mis en œuvre dans la formulation d’une composition biphasique selon l’invention.Most of the preservatives, authorized or not authorized by the regulations (appendix V of the European Directive on cosmetic products), suitable for use in cosmetic or dermatological compositions can be implemented in the formulation of a biphasic composition according to the 'invention.
Selon un mode de réalisation avantageux, la composition est exempte du conservateur chlorure de benzéthonium. En d’autres termes, la composition selon l’invention comprend en outre au moins un agent conservateur, à l’exception du chlorure de benzéthonium.According to an advantageous embodiment, the composition is free of the preservative benzethonium chloride. In other words, the composition according to the invention also comprises at least one preservative, with the exception of benzethonium chloride.
Selon un mode de réalisation particulier, le conservateur selon l’invention est un alcanediol.According to a particular embodiment, the preservative according to the invention is an alkanediol.
Avantageusement, le conservateur selon l’invention est un 1,2-alcanediol ou un 1,3-alcanediol ou leurs mélanges.Advantageously, the preservative according to the invention is a 1,2-alkanediol or a 1,3-alkanediol or their mixtures.
Selon un mode de réalisation particulier, l’alcanediol est choisi dans le groupe comprenant les composés correspondants aux désignations INCI suivantes : propylene glycol, 1,3-propanediol, 2-methyl-1,3-propanediol, 1,2-pentanediol, 1,2-hexanediol, caprylyl glycol, 1,2-decanediol, 2-methyl-2,4-pentanediol et leurs mélanges.According to a particular embodiment, the alkanediol is chosen from the group comprising the compounds corresponding to the following INCI designations: propylene glycol, 1,3-propanediol, 2-methyl-1,3-propanediol, 1,2-pentanediol, 1 ,2-hexanediol, caprylyl glycol, 1,2-decanediol, 2-methyl-2,4-pentanediol and mixtures thereof.
Ces conservateurs sont disponibles auprès de plusieurs fournisseurs de matières premières cosmétiques. A titre d’exemple, on peut citer :
- le EVO-100™ commercialisé par la société ARCHER DANIELS MIDLAND COMPANY et correspondant à la désignation INCI propylene glycol ;
- le ZEMEA™ commercialisé par la société DUPONT-TATE & LYLE BIOPRODUCTS et correspondant à la désignation INCI 1,2-propanediol ;
- le DUB DIOL™ commercialisé par la société STEARINERIE DUBOIS et correspondant à la désignations INCI 2-methyl-1,3-propanediol ;
- l’Hydrolite-5™, Hydrolite-6™, Hydrolite-8™ et le SymClariol 344028™ commercialisés par la société SYMRISE et correspondant respectivement aux désignations INCI 1,2-pentanediol, 1,2-hexanediol, caprylyl glycol et 1,2-decanediol ;
- l’Hexasol™ commercialisé par la société ARKEMA et correspondant à la désignation INCI hexylene glycol.These preservatives are available from several suppliers of cosmetic raw materials. By way of example, we can cite:
- EVO-100™ marketed by ARCHER DANIELS MIDLAND COMPANY and corresponding to the INCI designation propylene glycol;
- ZEMEA™ marketed by the company DUPONT-TATE & LYLE BIOPRODUCTS and corresponding to the INCI designation 1,2-propanediol;
- DUB DIOL™ marketed by the company STEARINERIE DUBOIS and corresponding to the INCI designations 2-methyl-1,3-propanediol;
- Hydrolite-5™, Hydrolite-6™, Hydrolite-8™ and SymClariol 344028™ marketed by the company SYMRISE and corresponding respectively to the INCI designations 1,2-pentanediol, 1,2-hexanediol, caprylyl glycol and 1, 2-decanediol;
- Hexasol™ marketed by ARKEMA and corresponding to the INCI designation hexylene glycol.
D’autres conservateurs adaptés à une utilisation dans la composition biphasique selon l’invention sont, par exemple :
- le potassium sorbate (INCI), le sodium benzoate (INCI) et le benzyl alcohol (INCI) commercialisés par la société AZELIS UK sous la dénomination Paratexin™ KS, Paratexin™ SBG et Paratexin™ BA, respectivement ;
- le p-anisic acid (INCI) et levulinic acid (INCI) commercialisés par la société COSPHATEC GMBH sous la dénomination Cosphaderm™ et Cophaderm™ LA-T, respectivement ;
- le dehydroacetic acid (INCI) et le polyaminoprypyl guanide (INCI), commercialisés par la société LONZA sous la dénomination Geogard™ 111A et Cosmocil™ CQ, respectivement ;
- le phenoxyethanol (INCI) commercialisé par la société CLARIANT INTERNATIONAL LTD sous la dénomination Phenoxetol™ ;
- le o-cymen-5-ol (INCI) commercialisé par la société JAN DEKKER sous la dénomination BIOSOL ;
- la capryloyl glycine (INCI), commercialisée par la société SEPPIC AIR LIQUIDE sous la dénomination LIPACIDE C8G ;
- le copper sulfate (INCI) commercialisé par la société COOPER INDUSTRIE sous la dénomination CUIVRE SULFATE 5H2O ; et
- le zinc sulfate (INCI) commercialisé par la société MERCK sous la dénomination ZINC SULFATE 7H2O.Other preservatives suitable for use in the biphasic composition according to the invention are, for example:
- potassium sorbate (INCI), sodium benzoate (INCI) and benzyl alcohol (INCI) marketed by the company AZELIS UK under the name Paratexin™ KS, Paratexin™ SBG and Paratexin™ BA, respectively;
- p-anisic acid (INCI) and levulinic acid (INCI) marketed by the company COSPHATEC GMBH under the names Cosphaderm™ and Cophaderm™ LA-T, respectively;
- dehydroacetic acid (INCI) and polyaminoprypyl guanide (INCI), marketed by the company LONZA under the names Geogard™ 111A and Cosmocil™ CQ, respectively;
- phenoxyethanol (INCI) marketed by CLARIANT INTERNATIONAL LTD under the name Phenoxetol™;
- o-cymen-5-ol (INCI) marketed by the company JAN DEKKER under the name BIOSOL;
- capryloyl glycine (INCI), marketed by the company SEPPIC AIR LIQUIDE under the name LIPACIDE C8G;
- copper sulphate (INCI) marketed by the company COOPER INDUSTRIE under the name CUIVRE SULFATE 5H 2 O; and
- zinc sulphate (INCI) marketed by the company MERCK under the name ZINC SULFATE 7H 2 O.
Selon un mode de réalisation particulier, la composition biphasique selon l’invention comprend un ou plusieurs agent conservateur représentant, avantageusement, entre 0,001% et 5% en poids total de la composition, de préférence entre 0,01% et 2%, plus préférentiellement entre 0,1% et 1%.According to a particular embodiment, the biphasic composition according to the invention comprises one or more preservatives representing, advantageously, between 0.001% and 5% by total weight of the composition, preferably between 0.01% and 2%, more preferentially between 0.1% and 1%.
La composition selon l’invention peut également contenir des adjuvants comme ceux habituellement utilisés dans le domaine de la cosmétique, tels que des antioxydants, des agents complexants, des solvants, des parfums, des charges, des électrolytes, des absorbeurs d'odeur, des matières colorantes. Le choix de ces adjuvants, ainsi que leurs concentrations, doivent être déterminés de telle sorte qu'ils ne modifient pas les propriétés et les avantages recherchés pour la composition de la présente invention.The composition according to the invention may also contain adjuvants such as those usually used in the field of cosmetics, such as antioxidants, complexing agents, solvents, perfumes, fillers, electrolytes, odor absorbers, coloring matter. The choice of these adjuvants, as well as their concentrations, must be determined so that they do not modify the properties and the advantages sought for the composition of the present invention.
L’invention concerne également une composition cosmétique biphasique telle que définie précédemment caractérisée en ce qu’il s’agit une composition démaquillante ou de nettoyage de la peau, des muqueuses et/ou des phanères, avantageusement d’une composition démaquillante.The invention also relates to a biphasic cosmetic composition as defined above, characterized in that it is a makeup-removing or cleansing composition for the skin, mucous membranes and/or appendages, advantageously a makeup-removing composition.
Selon un autre aspect, l’invention concerne également un procédé cosmétique de démaquillage, de nettoyage et/ou de soin de la peau et/ou des lèvres et/ou des yeux et/ou des cheveux.According to another aspect, the invention also relates to a cosmetic process for removing make-up, for cleaning and/or caring for the skin and/or the lips and/or the eyes and/or the hair.
Ainsi, ce procédé cosmétique comprend les étapes suivantes :
- agiter la composition cosmétique biphasique telle que décrite précédemment afin de former une émulsion extemporanée ; et
- appliquer ladite composition se présentant sous la forme d’une émulsion sur la peau et/ou les lèvres et/ou les yeux et/ou les cheveux.Thus, this cosmetic process comprises the following steps:
- Shake the biphasic cosmetic composition as described above in order to form an extemporaneous emulsion; and
- applying said composition in the form of an emulsion to the skin and/or the lips and/or the eyes and/or the hair.
Selon encore un autre aspect l’invention concerne un procédé pour prolonger les temps de déphasage d’une composition biphasique, avantageusement d’une composition cosmétique biphasique, comprenant une phase grasse et une phase aqueuse, la dite méthode consistant à introduire dans le composition démaquillante un ester d'acide gras et de glycérol sélectionné dans le groupe constitué du laurate de polyglycéryl-10, caprylate de polyglycéryl-3, caprate de polyglycéryl-3, caprate de polyglycéryl-4, laurate de polyglycéryl-2, laurate de polyglycéryl-5, caprylate de glycéryle, laurate de glycéryle, myristate de glycéryle, stéarate de glycéryle, undécylénate de glycéryle, caprylate/caprate de glycéryle et leurs mélanges, avantageusement le laurate de polyglycéryl-10.According to yet another aspect, the invention relates to a method for prolonging the phase shift times of a biphasic composition, advantageously of a biphasic cosmetic composition, comprising a fatty phase and an aqueous phase, the said method consisting in introducing into the make-up remover composition a fatty acid glycerol ester selected from the group consisting of polyglyceryl-10 laurate, polyglyceryl-3 caprylate, polyglyceryl-3 caprate, polyglyceryl-4 caprate, polyglyceryl-2 laurate, polyglyceryl-5 laurate , glyceryl caprylate, glyceryl laurate, glyceryl myristate, glyceryl stearate, glyceryl undecylenate, glyceryl caprylate/caprate and mixtures thereof, advantageously polyglyceryl-10 laurate.
La manière dont l’invention peut être réalisée et les avantages qui en découlent ressortiront mieux des exemples de réalisation qui suivent, données à titre indicatif et non limitatif.The way in which the invention can be implemented and the resulting advantages will emerge better from the examples of embodiment which follow, given by way of indication and not limitation.
Les exemples ci-après font partie intégrante de l’invention et toute caractéristique qui apparait être nouvelle par rapport à l’état de la technique antérieure est revendiquée en tant que telle et en tant que moyen général.The examples below form an integral part of the invention and any characteristic which appears to be new in relation to the state of the prior art is claimed as such and as a general means.
Exemples de réalisationExamples of realization
Exemple I – Formulation d’une composition démaquillant biphasique selon l’inventionExample I - Formulation of a biphasic make-up remover composition according to the invention
Une formulation de composition cosmétique démaquillante biphasique selon l’invention est présentée dans le tableau 1 ci-dessous.A biphasic makeup-removing cosmetic composition formulation according to the invention is presented in Table 1 below.
Les caractéristiques électroniques de la phase aqueuse de la formule du tableau 1 sont indiquées dans le tableau 2 ci-dessous.The electronic characteristics of the aqueous phase of the formula of Table 1 are indicated in Table 2 below.
Exemple II- Evaluation du temps de déphasage d’une composition biphasique selon l’invention et comparaison par rapport à des compositions de l’état de la techniqueExample II-Evaluation of the phase shift time of a biphasic composition according to the invention and comparison with compositions of the state of the art
II-1 IntroductionII-1 Introduction
L’objectif de l’étude était de comparer la vitesse de séparation de phase d’une composition selon l’invention (Fle 1) par rapport à celle de plusieurs compositions selon l’état de la technique (Fle 2 à Fle 5) et à une formulation témoin (Fle T).The objective of the study was to compare the phase separation rate of a composition according to the invention (Fle 1) with that of several compositions according to the state of the art (Fle 2 to Fle 5) and to a control formulation (Fle T).
II-2 Matériels et méthodesII-2 Materials and methods
Des formules biphasiques contenant une phase aqueuse représentant 70% en poids total de la composition de et une phase grasse représentant 30% en poids total de la composition ont été préparées.Biphasic formulas containing an aqueous phase representing 70% by total weight of the composition and a fatty phase representing 30% by total weight of the composition were prepared.
Les formules préparées contiennent la même quantité de différents tensioactifs, à savoir :
- la composition selon l’invention, correspondant à la formule 1 (Fle 1), comprend du polyglyceryl-10 laurate;
- les compositions correspondant aux formules 2 à 4 (Fle 2 à 4), comprennent chacune un tensioactif selon l’état de la technique ; et
- la composition correspondant à la formule témoin (Fle T) ne comprenant pas de tensioactif (témoin négatif).The formulas prepared contain the same amount of different surfactants, namely:
- the composition according to the invention, corresponding to formula 1 (Fle 1), comprises polyglyceryl-10 laurate;
- the compositions corresponding to formulas 2 to 4 (Fle 2 to 4), each comprise a surfactant according to the state of the art; and
- the composition corresponding to the control formula (Fle T) not comprising any surfactant (negative control).
Les essais ont été réalisés à température ambiante sur 420g de composition biphasique. Les formules ont été agitées sous le même agitateur magnétique 1200 rpm pendant 1 minute avec le même barreau aimanté. Par la suite, le temps nécessaire à l’obtention d’un déphasage total a été mesuré.The tests were carried out at ambient temperature on 420 g of biphasic composition. The formulas were stirred under the same magnetic stirrer at 1200 rpm for 1 minute with the same magnetic bar. Subsequently, the time required to obtain a total phase shift was measured.
Les formules suivantes, représentées dans le tableau 3, ont été testées :The following formulas, shown in Table 3, were tested:
La composition de la formule selon l’invention est identique à celle du tableau 1. Les caractéristiques électroniques de la phase aqueuse sont donc celles indiquées dans le tableau 2.The composition of the formula according to the invention is identical to that of table 1. The electronic characteristics of the aqueous phase are therefore those indicated in table 2.
II-3 Résultats et conclusions II -3 Results and conclusions
Les résultats sont présentés dans le tableau 4 ci-dessous :The results are presented in Table 4 below:
En absence de tensioactif, la séparation entre les deux phases intervient 9 minutes après l’étape d’agitation visant à produire l’émulsion. Les tensioactifs octyldodecyl xyloside et caprylyl/capryl glucoside réduisent le temps de déphasage par rapport à ce qui est observé en absence de tensioactif. Le tensioactif Poloxamer 184 augmente le temps de déphasage (25 min) mais l’augmentation maximale du temps de déphasage est obtenue avec un tensioactif selon l’invention, à savoir le polyglyceryl-10 laurate (fle 1 ; temps de déphasage >1 heure).In the absence of surfactant, the separation between the two phases occurs 9 minutes after the stirring step aimed at producing the emulsion. The octyldodecyl xyloside and caprylyl/capryl glucoside surfactants reduce the phase shift time compared to what is observed in the absence of surfactant. The surfactant Poloxamer 184 increases the phase shift time (25 min) but the maximum increase in the phase shift time is obtained with a surfactant according to the invention, namely polyglyceryl-10 laurate (fle 1; phase shift time >1 hour) .
Claims (17)
ladite composition comprend au moins un tensioactif ;
ledit tensioactif étant un ester d'acide gras et de glycérol sélectionné dans le groupe constitué du laurate de polyglycéryl-10, caprylate de polyglycéryl-3, caprate de polyglycéryl-3, caprate de polyglycéryl-4, laurate de polyglycéryl-2, laurate de polyglycéryl-5, caprylate de glycéryle, laurate de glycéryle, myristate de glycéryle, stéarate de glycéryle, undécylénate de glycéryle et caprylate/caprate de glycéryle ;
ladite phase grasse étant exempte de silicone.Biphasic ecobiological cosmetic composition comprising an aqueous phase and a distinct fatty phase in the form of two immiscible phases each present in continuous form;
said composition comprises at least one surfactant;
said surfactant being a glycerol fatty acid ester selected from the group consisting of polyglyceryl-10 laurate, polyglyceryl-3 caprylate, polyglyceryl-3 caprate, polyglyceryl-4 caprate, polyglyceryl-2 laurate, polyglyceryl-5, glyceryl caprylate, glyceryl laurate, glyceryl myristate, glyceryl stearate, glyceryl undecylenate and glyceryl caprylate/caprate;
said fatty phase being free of silicone.
-les alcanes ramifiés comprenant de 8 à 19 atomes de carbone et avantageusement sélectionnés dans le groupe constitué par l'isododécane, l'isodécane, l'isohexadécane, le C15-19 Alkane et leurs mélanges, avantageusement l’isohéxadecane et l’isododécane ;
- les dérivés huileux de glycérine, avantageusement les triglycérides d'acide caprique et/ou caprylique, le caprylate de glycérol, le caprate de glycérol et/ou le polyglyceryl-2 caprate ;
- les alcanes linéaires comprenant de 7 à 14 atomes de carbone ;
- les esters issus de la réaction d'au moins un acide gras comportant au moins 6 atomes de carbone, avantageusement de 6 à 26 atomes de carbone ;
- les éthers d'alcools gras comprenant de 6 à 20 atomes de carbone, avantageusement de 8 à 12 atomes de carbone, de préférence de 8 à 10 atomes de carbone ; et
- les triterpènes, avantageusement le squalane.Cosmetic composition according to Claim 6, characterized in that the fatty phase comprises at least one oil selected from the group consisting of:
-branched alkanes comprising from 8 to 19 carbon atoms and advantageously selected from the group consisting of isododecane, isododecane, isohexadecane, C15-19 Alkane and mixtures thereof, advantageously isododecane and isododecane;
- oily glycerol derivatives, advantageously capric and/or caprylic acid triglycerides, glycerol caprylate, glycerol caprate and/or polyglyceryl-2 caprate;
- linear alkanes comprising from 7 to 14 carbon atoms;
- esters resulting from the reaction of at least one fatty acid comprising at least 6 carbon atoms, advantageously from 6 to 26 carbon atoms;
- fatty alcohol ethers comprising from 6 to 20 carbon atoms, advantageously from 8 to 12 carbon atoms, preferably from 8 to 10 carbon atoms; and
- triterpenes, advantageously squalane.
- comprise entre 4 et 8, en ce qui concerne le pH ;
- comprise entre 10 et 300 mV, en ce qui concerne le potentiel redox ; et
- substantiellement comprise entre 33 et 8000 Ohms.cm, en ce qui concerne la résisitivité.Cosmetic composition according to any one of the preceding claims, characterized in that at least two bioelectric parameters of the said aqueous phase, one of which is the redox potential, and the other of which is chosen between the pH and the resistivity, are set to have a value:
- between 4 and 8, as regards the pH;
- between 10 and 300 mV, as regards the redox potential; and
- substantially between 33 and 8000 Ohms.cm, as regards the resistivity.
- agiter la composition cosmétique selon l’une quelconque des revendications 1 à 16 afin de former une émulsion extemporanée ;
- appliquer ladite composition se présentant sous la forme d’une émulsion sur la peau et/ou les lèvres et/ou les yeux et/ou les cheveux.Cosmetic process for removing make-up, cleaning and/or caring for the skin and/or the lips and/or the eyes and/or the hair, comprising the following steps:
- agitate the cosmetic composition according to any one of claims 1 to 16 in order to form an extemporaneous emulsion;
- applying said composition in the form of an emulsion to the skin and/or the lips and/or the eyes and/or the hair.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR2104190A FR3122091B1 (en) | 2021-04-22 | 2021-04-22 | ECOBIOLOGICAL BIPHASIC COSMETIC COMPOSITION WITH DELAYED PHASES SEPARATION |
PCT/FR2022/050763 WO2022223933A1 (en) | 2021-04-22 | 2022-04-21 | Organic two-phase cosmetic composition with delayed phase separation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR2104190 | 2021-04-22 | ||
FR2104190A FR3122091B1 (en) | 2021-04-22 | 2021-04-22 | ECOBIOLOGICAL BIPHASIC COSMETIC COMPOSITION WITH DELAYED PHASES SEPARATION |
Publications (2)
Publication Number | Publication Date |
---|---|
FR3122091A1 true FR3122091A1 (en) | 2022-10-28 |
FR3122091B1 FR3122091B1 (en) | 2023-12-29 |
Family
ID=77021428
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR2104190A Active FR3122091B1 (en) | 2021-04-22 | 2021-04-22 | ECOBIOLOGICAL BIPHASIC COSMETIC COMPOSITION WITH DELAYED PHASES SEPARATION |
Country Status (2)
Country | Link |
---|---|
FR (1) | FR3122091B1 (en) |
WO (1) | WO2022223933A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024127300A1 (en) * | 2022-12-16 | 2024-06-20 | L'oreal | Micellar bi-phase makeup spray in a non-aerosol fine mist packaging |
FR3147499A1 (en) * | 2023-04-07 | 2024-10-11 | L'oreal | BI-PHASIC MICELLAR MAKEUP SPRAY IN NON-AEROSOL FINE MIST PACKAGING |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2935264A1 (en) | 2008-09-02 | 2010-03-05 | Oreal | CLEANSING COMPOSITION COMPRISING A VOLATILE FATTY PHASE. |
FR2971421A1 (en) | 2011-02-16 | 2012-08-17 | Oreal | Composition, useful e.g. for removing make-up and cleaning skin, comprises hydrophilic phase e.g. polycondensate of ethylene oxide, and separate oily phase comprising oil fatty acid ester and cyclic silicone oil |
FR2993177A1 (en) | 2012-07-16 | 2014-01-17 | Oreal | BIPHASIC COMPOSITION CONTAINING ALKYLPOLYGLUCOSIDE AND A FUSION POINT ESTER LESS THAN 10 ° C |
FR3012330A1 (en) | 2013-10-29 | 2015-05-01 | Oreal | BIPHASE COMPOSITION COMPRISING AN ESTER OF FATTY ACID AND SUGAR OR A LIQUID ALKYLPOLYGLUCOSIDE OF HLB <8, AND A C8-C18 BRANCHED ALKANE |
WO2016146360A1 (en) * | 2015-03-16 | 2016-09-22 | Beiersdorf Ag | Multi-functional preparation for facial cleansing |
FR3049459A1 (en) * | 2016-04-01 | 2017-10-06 | Chanel Parfums Beaute | BIPHASE CLEANING COMPOSITION |
-
2021
- 2021-04-22 FR FR2104190A patent/FR3122091B1/en active Active
-
2022
- 2022-04-21 WO PCT/FR2022/050763 patent/WO2022223933A1/en active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2935264A1 (en) | 2008-09-02 | 2010-03-05 | Oreal | CLEANSING COMPOSITION COMPRISING A VOLATILE FATTY PHASE. |
FR2971421A1 (en) | 2011-02-16 | 2012-08-17 | Oreal | Composition, useful e.g. for removing make-up and cleaning skin, comprises hydrophilic phase e.g. polycondensate of ethylene oxide, and separate oily phase comprising oil fatty acid ester and cyclic silicone oil |
FR2993177A1 (en) | 2012-07-16 | 2014-01-17 | Oreal | BIPHASIC COMPOSITION CONTAINING ALKYLPOLYGLUCOSIDE AND A FUSION POINT ESTER LESS THAN 10 ° C |
FR3012330A1 (en) | 2013-10-29 | 2015-05-01 | Oreal | BIPHASE COMPOSITION COMPRISING AN ESTER OF FATTY ACID AND SUGAR OR A LIQUID ALKYLPOLYGLUCOSIDE OF HLB <8, AND A C8-C18 BRANCHED ALKANE |
WO2016146360A1 (en) * | 2015-03-16 | 2016-09-22 | Beiersdorf Ag | Multi-functional preparation for facial cleansing |
FR3049459A1 (en) * | 2016-04-01 | 2017-10-06 | Chanel Parfums Beaute | BIPHASE CLEANING COMPOSITION |
Non-Patent Citations (4)
Title |
---|
DATABASE GNPD [online] MINTEL; 12 May 2020 (2020-05-12), ANONYMOUS: "Two-Phase Eye Makeup Remover", XP055872850, retrieved from https://www.gnpd.com/sinatra/recordpage/7611335/ Database accession no. 7611335 * |
DATABASE GNPD [online] MINTEL; 20 January 2021 (2021-01-20), ANONYMOUS: "Light Reflecting Firming Serum", XP055872827, retrieved from https://www.gnpd.com/sinatra/recordpage/8381797/ Database accession no. 8381797 * |
DATABASE GNPD [online] MINTEL; 5 May 2020 (2020-05-05), ANONYMOUS: "Aqua Triple Oil Cleanser", XP055872848, retrieved from https://www.gnpd.com/sinatra/recordpage/7599717/ Database accession no. 7599717 * |
DATABASE GNPD [online] MINTEL; 6 March 2020 (2020-03-06), ANONYMOUS: "Dual Phase Pore Clear Micellar Water", XP055826692, retrieved from https://www.gnpd.com/sinatra/recordpage/7421031/ Database accession no. 7421031 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024127300A1 (en) * | 2022-12-16 | 2024-06-20 | L'oreal | Micellar bi-phase makeup spray in a non-aerosol fine mist packaging |
FR3147499A1 (en) * | 2023-04-07 | 2024-10-11 | L'oreal | BI-PHASIC MICELLAR MAKEUP SPRAY IN NON-AEROSOL FINE MIST PACKAGING |
Also Published As
Publication number | Publication date |
---|---|
FR3122091B1 (en) | 2023-12-29 |
WO2022223933A1 (en) | 2022-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2483228B1 (en) | Utilisation of a vanilline derivative as preservative, process of preservation, compounds and composition | |
EP1027878A1 (en) | Cosmetic and/or dermatological composition in the form of an oil-in-water emulsion formed by lipid vesicles dispersed in an aqueous phase containing at least one active hydrophilic acid | |
EP3554462A1 (en) | Method for improving the sensorial properties of oil-in-water emulsions | |
FR3122091A1 (en) | ECOBIOLOGICAL BIPHASIC COSMETIC COMPOSITION WITH DELAYED PHASE SEPARATION | |
EP3466419B1 (en) | Use of trimethoxybenzyl acetylsinapate, advantageously in combination with at least one sunscreen, for protecting the skin | |
EP3818973B1 (en) | Water-resistant solar composition with high triazine content | |
US9833401B2 (en) | Method for producing composition for external use containing physiologically acceptable salt of tranexamate | |
WO2022254116A1 (en) | Cosmetic use of an oily extract from solid residue of immortelle as a skin brightening agent | |
EP1466589B1 (en) | Stable cosmetic composition comprising a fatty acid glyceride, an alcohol and a silicone emulsifier | |
FR3076722A1 (en) | SYNERGIC ASSOCIATION OF TÉTRAPEPTIDES | |
FR3021528A1 (en) | COSMETIC FORMULATION | |
EP0985409A1 (en) | Cosmetic use of fatty acids | |
FR3007652A1 (en) | COMPOSITION COMPRISING DOCOSAHEXAENOIC ACID AND PENTAERYTHRITYL TETRA-DI-T-BUTYL HYDROXYHYDROCINNAMATE | |
WO2022129382A1 (en) | Glycosylated bacterioruberins and industrial applications thereof | |
FR2958546A1 (en) | USE OF GLYCOPEPTIDES RICH IN SOYA HYDROXYPROLINE TO FIGHT THE APPEARANCE OF WRINKLES | |
FR3055214A1 (en) | LIGHTENING COSMETIC COMPOSITION | |
FR3021539A1 (en) | COSMETIC AND / OR DERMATOLOGICAL COMPOSITION COMPRISING A VEGETABLE EXTRACT AND A GENE ACTIVATOR | |
FR3114237A1 (en) | Cosmetic composition with evolving texture in the form of a water-in-oil emulsion | |
WO2023180126A1 (en) | Cosmetic use of a combination of immortelle extracts to reduce the visibility of skin pores | |
WO2024194369A1 (en) | Process for the preparation of a polar lipid-enriched algal extract | |
FR3142344A1 (en) | Retinol-based composition | |
FR3133125A1 (en) | cosmetic compositions in the form of phase-saturated emulsions and their use in topical application. | |
FR3128881A1 (en) | Sunscreen composition including organic UV filters and environmentally friendly oily copolymers | |
WO2024194370A1 (en) | Himanthalia elongata extract, cosmetic composition comprising same, and uses thereof | |
FR3131216A1 (en) | SKIN CARE COMPOSITION |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PLFP | Fee payment |
Year of fee payment: 2 |
|
PLSC | Publication of the preliminary search report |
Effective date: 20221028 |
|
PLFP | Fee payment |
Year of fee payment: 3 |
|
CL | Concession to grant licences |
Name of requester: NAOS INSTITUTE OF LIFE SCIENCE, FR Effective date: 20230724 |
|
AU | Other action affecting the ownership or exploitation of an industrial property right |
Effective date: 20231016 |
|
CL | Concession to grant licences |
Name of requester: NAOS, FR Effective date: 20231016 Name of requester: NAOS INSTITUTE OF LIFE SCIENCE, FR Effective date: 20231016 |
|
PLFP | Fee payment |
Year of fee payment: 4 |